<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Acta Naturae</journal-id>
<journal-id journal-id-type="iso-abbrev">Acta Naturae</journal-id>
<journal-id journal-id-type="publisher-id">ActaNaturae</journal-id>
<journal-title-group>
<journal-title>Acta Naturae</journal-title>
</journal-title-group>
<issn pub-type="ppub">2075-8251</issn>
<publisher>
<publisher-name>A.I. Gordeyev</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28461971</article-id>
<article-id pub-id-type="pmc">5406657</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Research Article</subject>
<subj-group>
<subject>Molecular Biology</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Cholesterol in the Pathogenesis of Alzheimer’s, Parkinson’s Diseases and Autism: Link to Synaptic Dysfunction</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Petrov</surname>
<given-names>A. M.</given-names>
</name>
<xref ref-type="aff" rid="AF1"></xref>
<email>fysio@rambler.ru</email>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kasimov</surname>
<given-names>M. R.</given-names>
</name>
<xref ref-type="aff" rid="AF1"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zefirov</surname>
<given-names>A. L.</given-names>
</name>
<xref ref-type="aff" rid="AF1"></xref>
</contrib>
</contrib-group>
<aff id="AF1">Kazan State Medical University, Normal Physiology department, Butlerova str. 49, Kazan, 420012, Russia</aff>
<pub-date pub-type="ppub">
<season>Jan-Mar</season>
<year>2017</year>
</pub-date>
<volume>9</volume>
<issue>1</issue>
<fpage>26</fpage>
<lpage>37</lpage>
<history>
<date date-type="received">
<day>28</day>
<month>11</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright ® 2017 Park-media Ltd.</copyright-statement>
<copyright-year>2017</copyright-year>
<license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0/">
<license-p>
This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.
</license-p>
</license>
</permissions>
<abstract>
<p>
In our previous review, we described brain cholesterol metabolism in control
conditions and in the case of some rare neurological pathologies linked to
defects in the genes which are directly involved in the synthesis and/or
traffic of cholesterol. Here, we have analyzed disruptions in cholesterol
homeostasis in widespread neurodegenerative diseases (Alzheimer’s and
Parkinson’s diseases) and autism spectrum disorders. We particularly
focused on the synaptic dysfunctions that could arise from changes in both
membrane cholesterol availability and oxysterol production. Notably,
alterations in the brain cholesterol metabolism and neurotransmission occur in
the early stages of these pathologies and the polymorphism of the genes
associated with cholesterol homeostasis and synaptic communication affects the
risk of onset and severity of these diseases. In addition, pharmacological and
genetic manipulations of brain cholesterol homeostasis in animal models
frequently have marked effects on the progression of neurodegenerative
diseases. Thus, the development of Alzheimer’s, Parkinson’s and
autism spectrum disorders may be partially associated with an imbalance of
cholesterol homeostasis that leads to changes in the membrane cholesterol and
oxysterol levels that, in turn, modulates key steps in the synaptic
transmission.
</p>
</abstract>
<kwd-group kwd-group-type="author">
<kwd>cholesterol</kwd>
<kwd>oxysterols</kwd>
<kwd>lipid rafts</kwd>
<kwd>neurodegenerative disease</kwd>
<kwd>synaptic transmission</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec>
<title>INTRODUCTION</title>
<p>
Previously, we described changes in cholesterol metabolism in rare hereditary
pathologies of the central nervous system caused by mutations in the genes
which are directly involved in the biosynthesis of cholesterol
(Smith-Lemli-Opitz syndrome) or its intracellular traffic (Niemann-Pick type C
disease) and synthesis regulation (Huntington disease)
[<xref ref-type="bibr" rid="R1">1</xref>]. In this review, we analyze the
relationships between such common neurodegenerative diseases as
Alzheimer’s and Parkinson’s and autism spectrum disorders and
cholesterol homeostasis and synaptic dysfunction.
</p>
</sec>
<sec>
<title>ALZHEIMER’S DISEASE (AD)</title>
<p>
Alzheimer’s disease is the most widespread neurodegenerative disease. It
usually affects older people and manifests itself as a deterioration of memory
and cognitive abilities. It involves the deposition of amyloid peptide β
(Aβ) into amyloid plaques in the extracellular space of the brain and
neurofilament bundles of the hyperphosphorylated tau protein inside cells. An
accumulation of Aβ and death of neurons, especially in the hippocampus,
are considered the main manifestations of AD. The accumulation of Aβ
reflects the imbalance between its production and its elimination from the
brain. Aβ is formed in a two-step cleavage of the transmembrane protein
APP (amyloid precursor protein) by proteases called secretases. The APP is
first cleaved by either secretase α or β, and then by γ. The
cleavage of APP by α-secretase results in a nonamyloidogenic product,
sAPPα, which does not cause the disease. Moreover, sAPPα has
neuroprotective effects and enhances long-term potentiation and learning
ability. APP is cleaved by β-secretase (BACE1) to release the soluble
fragment sAPPβ (involved in the elimination of synapses and apoptosis) and
a C-terminal fragment (βCTF) which is subsequently cut by γ-secretase
(a complex of several proteins comprising presenilin 1 or 2, APH, nicastrin and
PEN2) with the formation of toxic Aβ containing 40 or 42 (more toxic)
amino acid residues. In addition, βCTF proteolysis by γ-secretase
results in the release of the intracellular APP domain (AICD), which, in
cooperation with Fe65 and TIP60, can trigger the transcription of genes which
accelerate cell death and disrupt neurogenesis [<xref ref-type="bibr" rid="R2">2</xref>].
Aβ in the brain interstitial fluid can be removed via
several mechanisms: transfer through the BBB, uptake by cells for degradation
in the lysosomes, and cleavage by specific proteases
(<italic><xref ref-type="fig" rid="F1">Fig. 1A</xref></italic>).
Lysosomes contain a specific Aβ-degrading protease,
neprilysin, whereas outside the cell Aβ clearance is performed by an
insulin-degrading enzyme (IDE) which is secreted by astrocytes and microglia
[<xref ref-type="bibr" rid="R3">3</xref>]. There are two forms of AD: with
early (5–10%) and late (90–95%) onset in which the disease symptoms
appear before and after 65 years of age, respectively. The early form is
strictly hereditary and is associated with excessive production of Aβ.
Patients with a late onset type of AD usually have inefficient Aβ
clearance rather than an enhanced production
[<xref ref-type="bibr" rid="R4">4</xref>, <xref ref-type="bibr" rid="R5">5</xref>].
</p>
<fig id="F1" orientation="portrait" position="float">
<label>Fig. 1</label>
<caption>
<p>
Synthesis of amyloid peptide and brain level of cholesterol. A – Amyloid
precursor protein (APP) processing: involvement of α-, β- and
γ-secretases. B – Links between amyloid peptide β (Aβ)
production and brain cholesterol metabolism. Impact of cholesterol-rich diet.
See text for details.
</p>
</caption>
<graphic xlink:href="AN20758251-09-01-026-g001"></graphic>
</fig>
<p>
<bold>The levels of cholesterol in the brain and blood plasma: correlations
with AD, role of oxysterols</bold>
</p>
<p>
Experimental data support the significant contribution of changes in
cholesterol metabolism to the pathogenesis of AD
(<italic><xref ref-type="fig" rid="F1">Fig. 1B</xref></italic>).
However, it is unclear whether the disruption in cholesterol homeostasis is
a cause or a consequence of the disease. An earlier work revealed Aβ
accumulation in the brain of rabbits receiving a cholesterol-rich diet
[<xref ref-type="bibr" rid="R6">6</xref>]. Later research showed that cholesterol
intake increases tau phosphorylation, causes oxidative stress and cognitive
defects, but does not change the level of cholesterol in a rabbit’s brain
[<xref ref-type="bibr" rid="R7">7</xref>]. Several epidemiological studies (but
not all of them) found an increased risk of AD in individuals with elevated
plasma cholesterol, especially in mid-life
[<xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R8">8</xref>].
There is a confirmed correlation between high (or low) cholesterol content in low (high)
density lipoproteins and Aβ levels in the brain of patients in early
stages of AD [<xref ref-type="bibr" rid="R9">9</xref>]. However, the
relationship between cholesterol levels in plasma and AD may be mediated by
changes in the vascular tone and inflammatory responses rather than by direct
influence on the brain cholesterol. Chronic cerebral hypoperfusion in rats and
mice with AD increases BACE1 expression, Aβ concentration, and cognitive
defects [<xref ref-type="bibr" rid="R10">10</xref>]. Hypoperfusion and
inflammation, high levels of cholesterol in the plasma can cause AD-promoting
vascular dysfunction and changes in oxysterol production.
</p>
<p>
In AD, the concentration of 24S-hydroxycholesterol (24OH-Ch) decreases in the
brain. However, in patients at the initial stages of AD the level of 24OH-Ch
transiently increases in the plasma and cerebrospinal fluid
[<xref ref-type="bibr" rid="R11">11</xref>]. Individuals with elevated plasma
24OH-Ch have a higher probability of developing cognitive impairment over the next
8 years [<xref ref-type="bibr" rid="R12">12</xref>]. The excessive production of
24OH-Ch may be an indication of an attempt to compensate for the nascent
dysfunction [<xref ref-type="bibr" rid="R1">1</xref>]. Elevated expression of
the 24OH-Ch-synthesizing enzyme CYP46A1 (using adenoviral therapy) in the brain
of APP23-mice significantly reduces Aβ accumulation, gliosis, and
cognitive defects [<xref ref-type="bibr" rid="R13">13</xref>]. The effect of
CYP46A1 activation may be mediated by 24OH-Ch that stimulates LXα and
β-receptors, which, in turn, increases the expression of the genes
involved in cholesterol synthesis and traffic [<xref ref-type="bibr" rid="R1">1</xref>].
Deletion of LXα or β-receptor genes causes
age-related neurodegenerative disorders [<xref ref-type="bibr" rid="R14">14</xref>].
Conversely, activation of LX-receptors increases Aβ
clearance and reverses the memory deficit in transgenic APP/PS1 and APP23 mice,
probably by upregulating the levels of ApoE and ABCA1 in the brain
[<xref ref-type="bibr" rid="R15">15</xref>]. ABCA1 can quickly remove the excess
Aβ from the membrane into the extracellular space that protects neurons
from the toxic effect of Aβ accumulation [<xref ref-type="bibr" rid="R16">16</xref>].
In the endothelial cells of brain capillaries, 24OH-Ch increases Aβ clearance,
enhancing the expression of ABCA1, and reduces Aβ production,
altering secretase expression [<xref ref-type="bibr" rid="R17">17</xref>].
</p>
<p>
The level of 27OH-Ch in the brain is significantly higher in AD
[<xref ref-type="bibr" rid="R18">18</xref>]. In rabbits receiving a diet rich in
cholesterol, the levels of 24OH-Ch and 27OH-Ch in the plasma increase, whereas
the ratio of 24OH-Ch to 27OH-Ch in the brain is lower, which may exacerbate the
risk of neurodegeneration. It is assumed that an increased influx of 27OH-Ch
into the brain and/or increased extrusion of 24OH-Ch from the brain may
underlie the association between a high level of cholesterol in the plasma and AD
[<xref ref-type="bibr" rid="R11">11</xref>, <xref ref-type="bibr" rid="R19">19</xref>].
Studies of organo-typical brain slices from adult animals
have shown that 27OH-Ch increases the levels of Aβ and phosphorylated tau,
whereas 24OH-Ch promotes nonamyloidogenic APP processing. Moreover, 24OH-Ch
inhibits the toxic effects of 27OH-Ch when these oxysterols are co-applied.
27OH-Ch can cause ER stress, resulting in the activation of the transcription
factor CHOP (C/EBPα homologous protein), which suppresses the leptin
synthesis that normally reduces BACE1 expression, Aβ production, and tau
phosphorylation [<xref ref-type="bibr" rid="R19">19</xref>].
</p>
<p>
Although early studies indicated that the level of brain cholesterol is
elevated in patients with AD, other researchers have found that brain
cholesterol synthesis and the total pool of cholesterol in the brain decrease
[<xref ref-type="bibr" rid="R8">8</xref>]
(<italic><xref ref-type="fig" rid="F1">Fig. 1B</xref></italic>).
In AD, the level of cholesterol is reduced in the temporal gyrus, hippocampus, lipid
raft fraction in the whole brain, and white matter
[<xref ref-type="bibr" rid="R20">20</xref>-<xref ref-type="bibr" rid="R22">22</xref>].
However, the cholesterol content is increased in the cores of mature amyloid plaques and the
nerve terminals enriched with amyloid aggregates [<xref ref-type="bibr" rid="R23">23</xref>].
These observations suggest the existence of an
Aβ-dependent mechanism of cholesterol removal from the nerve terminal
membrane. Other ways of lowering brain cholesterol availability in patients
with AD can be associated with: APP/Aβ-dependent supression of cholesterol
synthesis by inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase
(HMG-reductase) [<xref ref-type="bibr" rid="R24">24</xref>]; decrease in the
uptake of cholesterol-loaded ApoE-particles under the influence of Aβ
[<xref ref-type="bibr" rid="R15">15</xref>]; increase in cholesterol oxidation
due to enhanced CYP46A1 activity [<xref ref-type="bibr" rid="R11">11</xref>];
Aβ-induced modification of lipid rafts
[<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R25">25</xref>].
The increase in CYP46A1 activity may be caused by Aβ-induced alterations in
Ca<sup>2+</sup> homeostasis and oxidative stress
[<xref ref-type="bibr" rid="R11">11</xref>, <xref ref-type="bibr" rid="R26">26</xref>].
The aging process is accompanied by a reduction in the cholesterol content, especially
noticeable in regions susceptible to AD, which may be related to an increased
CYP46A1 expression/activity and decreased cholesterol synthesis/traffic
[<xref ref-type="bibr" rid="R26">26</xref>, <xref ref-type="bibr" rid="R27">27</xref>].
</p>
<p>
The brain biopsies of AD patients revealed an accumulation of cholesterol
ester-rich lipid drops in Aβ- positive neurons, and the higher the number
of such drops, the greater the concentration of Aβ
[<xref ref-type="bibr" rid="R28">28</xref>]. Inhibition of the synthesis of cholesterol
esters (acetyl-CoA-cholesterol acyltransferase/ACAT1) was accompanied by an increase
in 24-OH Ch concentration and a markedly reduced generation of Aβ, plaque
formation, and cognitive defects in an animal model of AD
[<xref ref-type="bibr" rid="R29">29</xref>]. It is possible that the early stages of
AD involve an increase in the synthesis of the enzymes responsible for the
formation of cholesterol esters [<xref ref-type="bibr" rid="R30">30</xref>].
One way to stimulate cholesterol esterification may be by increased production
of 25-OH Ch, which is caused by inflammation. In addition, the expression of
the CYP7B1 enzyme that metabolizes 25- and 27-OH Ch is downregulated in AD
[<xref ref-type="bibr" rid="R31">31</xref>].
</p>
<p>
The brain level of sphingomyelin is reduced in AD patients, and the
concentration of ceramides, products of sphingomyelin hydrolysis by
sphingomyelinases, is increased. Consequently, normal lipid rafts
“dissolve,” cholesterol is released from the membranes, and
ceramides aggregate to form large ceramide-enriched lipid platforms, which are
involved in the initiation of cell death. Sphingomyelinase activation may occur
in the early stages of AD in response to Aβ
[<xref ref-type="bibr" rid="R32">32</xref>, <xref ref-type="bibr" rid="R33">33</xref>].
The brain concentration of gangliosides (lipid raft components) decreases with aging, but
patients with AD show a steeper reduction. Aβ and AICD can inhibit and
reduce the expression of the enzymes required for the synthesis of several
gangliosides. However, the content of the gangliosides GM1 and GM2 involved in
Aβ aggregation increases in the AD brain
[<xref ref-type="bibr" rid="R21">21</xref>]. The imbalance in ganglioside
composition can contribute to the conversion of Aβ into a highly toxic oligomeric form
[<xref ref-type="bibr" rid="R1">1</xref>, <xref ref-type="bibr" rid="R33">33</xref>].
</p>
<p>
<bold>Aβ synthesis and cholesterol</bold>
</p>
<fig id="F2" orientation="portrait" position="float">
<label>Fig. 2</label>
<caption>
<p>
Cholesterol, lipid rafts and ApoE4 in the amyloid peptide β (Aβ)
turnover. A – Role of cholesterol and lipid rafts in the production and
toxicity of Aβ. B – Influence of ApoE4 on the Aβ
synthesis/clearance balance and neuron survival. See text for details.
</p>
</caption>
<graphic xlink:href="AN20758251-09-01-026-g002"></graphic>
</fig>
<p>
The extracellular N-terminal fragment of APP contains a cholesterol-binding
site [<xref ref-type="bibr" rid="R34">34</xref>], but most APP molecules are
located outside lipid rafts. Secretases β and γ, which are involved
in Aβ synthesis, are both residents of lipid rafts. Expression of the
scaffold protein RanBP9 (increased in APP-mice) promotes targeting of the APP
to lipid rafts, which contain BACE1 [<xref ref-type="bibr" rid="R35">35</xref>].
The activation of β-secretase requires lipid
rafts-dependent dimerization and stabilization steps. In the presence of
elevated levels of cholesterol and sphingolipis, raft-associated
γ-secretase produces a more toxic form, Aβ42. However, the synthesis
of Aβ (~ 70%) mainly occurs within a cell [<xref ref-type="bibr" rid="R28">28</xref>].
Therefore, it first requires the stage of raft-dependent
endocytosis, in which APP, β-, and γ-secretases uptake into a vesicle
and are then delivered to endosomes/lysosomes. Aβ is generated in the
endolysosomes under acidic conditions that favor BACE1 activity. Subsequently,
a portion of Aβ is released into the extracellular space by exocytosis
(e.g., as a content of synaptic vesicles) [<xref ref-type="bibr" rid="R3">3</xref>]
(<italic><xref ref-type="fig" rid="F2">Fig. 2A</xref></italic>).
Aβ aggregation into toxic oligomers is enhanced by zinc ions from synaptic vesicles
[<xref ref-type="bibr" rid="R36">36</xref>]. It should be noted that nonamyloidogenic
cleavage of APP by α-secretase occurs on the cell surface
[<xref ref-type="bibr" rid="R3">3</xref>].
</p>
<p>
The toxic effects of Aβ may depend on its binding to membrane components.
In the fibroblasts of AD patients, Aβ interacts with the plasma membrane
more actively when the cholesterol level is low, while high levels of
cholesterol prevent Aβ-induced generation of reactive oxygen species and
lipid oxidation [<xref ref-type="bibr" rid="R37">37</xref>]. On the other hand,
Aβ-mediated disruption of long-term synaptic potentiation and increased
synaptic depression may be caused by its binding to PrP (in this case,
metabotropic glutamate receptor 5 and LRP1 act as co-receptors) and the
subsequent activation of tyrosine kinase Fyn, which phosphorylates the tau
protein. A reduced integrity of rafts due to cholesterol removal disrupts the
complex of PrP-metabotropic glutamate receptor 5-LRP1, attenuating the
interaction of Aβ with the postsynaptic membranes
[<xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R38">38</xref>]
(<italic><xref ref-type="fig" rid="F2">Fig. 2A</xref></italic>).
</p>
<p>
From one point of view, the increase in membrane cholesterol promotes the
association of APP, β-, and γ-secretases within the lipid rafts and
increases Aβ production, while other authors suggest that APP and the
secretases are distributed into different rafts
[<xref ref-type="bibr" rid="R3">3</xref>, <xref ref-type="bibr" rid="R34">34</xref>, <xref ref-type="bibr" rid="R39">39</xref>].
A decreased membrane cholesterol content increases APP cleavage by α-secretase, reducing the formation of toxic
Aβ [<xref ref-type="bibr" rid="R3">3</xref>]. However, activation of the
plasminogen into the plasmin, which cuts Aβ, occurs on the surface of the
lipid rafts and, therefore, raft disruption can reduce the rate of Aβ
degradation [<xref ref-type="bibr" rid="R39">39</xref>]. Upon loss of raft
integrity, their components, in particular β- and γ-secretases, can
diffuse into the liquid-disordered membrane phase, where APP is mainly
distributed, and, therefore, Aβ production may increase
[<xref ref-type="bibr" rid="R32">32</xref>]. AD is associated with a reduced
expression of seladin-1 (selective Alzheimer disease indicator 1), a gene that
encodes an enzyme converting desmosterol to cholesterol. Deletion of seladin-1
leads to a lower cholesterol level, disorganization of lipid rafts, and Aβ
accumulation. Conversely, overexpression of seladin-1 (for example, in response
to estrogen administration) accelerates cholesterol metabolism in the brain and
increases neurons’ resistance to Aβ [<xref ref-type="bibr" rid="R40">40</xref>].
Interestingly, caveolin 1 gene knockout (caveolin 1
stabilizes the membrane rafts) leads to a pathology, similar to that observed
in AD, which is accompanied by Aβ accumulation and neurodegeneration. The
level of caveolin 1 in neurons reduces with aging, whereas the fluidity of the
synaptosomal membranes increases [<xref ref-type="bibr" rid="R41">41</xref>]. A
low expression of caveolin 1 reduces membrane cholesterol availability, since
caveolin 1 is involved in the delivery of newly synthesized cholesterol to the
plasma membrane [<xref ref-type="bibr" rid="R42">42</xref>].
</p>
<p>
Some studies indicate that pharmacological strategies for lowering the level of
cholesterol in cells, having its initial normal baseline level, inhibit Aβ
synthesis when APP is overexpressed. However, it is unclear how this conclusion
can be extrapolated to the disease or the process of normal aging, especially
if we consider the lowering of cholesterol levels in a normal and pathological
(in AD) aging brain [<xref ref-type="bibr" rid="R8">8</xref>]. A more likely
scenario is the one in which a decreased cholesterol level in neuronal
membranes, coupled with an increased Aβ production, a reduced Aβ
degradation, and an enhanced inflammatory response, contributes to the progression of AD
[<xref ref-type="bibr" rid="R22">22</xref>, <xref ref-type="bibr" rid="R39">39</xref>].
It should be noted that treatment with statins has no significant beneficial effect in AD, even though statins
significantly reduce plasma cholesterol levels
[<xref ref-type="bibr" rid="R43">43</xref>]. Moreover, several studies have
found cognitive deficits in response to statin treatments
[<xref ref-type="bibr" rid="R44">44</xref>];
so, in January 2014 the U.S. Food and Drug Administration (FDA) issued a
recommendation on the risks of statins. A promising finding is the use of
phytosterols in AD, which supress Aβ production <italic>in vitro
</italic>by inhibiting both the activity and expression of β- and
γ-secretases, and BACE1 internalization into endosomes. The effect of
phytosterols on Aβ processing may be associated with their stimulatory
action on LX-receptors or the ability to accumulate in lipid rafts; the later
facilitates the re-localization of APP and presenilin to a non-raft phase
[<xref ref-type="bibr" rid="R45">45</xref>].
</p>
<p>
<bold>ApoE and AD</bold>
</p>
<p>
Low levels of ApoE-particles in the brain correlate with an increase in the
risk of AD, but it is unclear whether this is associated with cholesterol
transport. By interacting with receptors, ApoE triggers anti-apoptotic
signaling pathways. ApoE binds to Aβ, then the complex passes through the
BBB with the help of LRP, thereby lowering the concentration of Aβ in the
brain. Aβ interaction with ApoE-particles is potentiated by sulfated
derivatives of galactocerebrosides, the concentration of which in the brain is lower in AD
[<xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R46">46</xref>, <xref ref-type="bibr" rid="R47">47</xref>].
An agonist of the nuclear retinoid X receptor rapidly increases the production of ApoE and
promotes Aβ degradation, decreasing the formation of Aβ-plaques
[<xref ref-type="bibr" rid="R48">48</xref>]. Oxysterol (24-OH Ch), which
promotes the expression of ApoE, ABCA1, and ABCG1 via the stimulation of
LX-receptors, has similar effects [<xref ref-type="bibr" rid="R1">1</xref>,
<xref ref-type="bibr" rid="R30">30</xref>].
</p>
<p>
There are three known human ApoE isoforms, which differ from each other only by
one amino acid residue. The most common allele is <italic>Apoε3,
</italic>while <italic>Apoε4 </italic>is detected only in 15–20% of
the population and is considered a risk factor for AD with late onset. The
probability of AD in individuals with one copy of <italic>Apoε4
</italic>is 4 times, and with two copies, 12–20 times higher than in
carriers of the <italic>Apoε3 </italic>allele. The presence of
<italic>Apoε2</italic>, conversely, hinders the progression of AD. Why
<italic>Apoε4 </italic>provokes the disease has not yet been established
[<xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R8">8</xref>].
There are several possibilities
[<xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R5">5</xref>,
<xref ref-type="bibr" rid="R48">48</xref>-<xref ref-type="bibr" rid="R51">51</xref>]:
1) ApoE4 binding to Aβ is weaker, causing less efficient clearance; 2)
ApoE4 is produced in smaller quantities, quickly decomposes, and does not form
dimers that promote Aβ degradation; in contrast, Aβ in a complex with
ApoE4 becomes resistant to degradation by neprilysin; 3) ApoE4 is less
effective in maintaining axonal growth and the survival of neurons; 4) ApoE4
promotes the endocytosis of APP and BACE1 and their targeting to early
endosomes, thereby increasing Aβ synthesis; 5) ApoE4 reduces the
expression of reelin receptors in synapses, blocking its protective properties
(<italic><xref ref-type="fig" rid="F2">Fig. 2B</xref></italic>).
</p>
<p>
In AD, the C-terminal fragment of ApoE that promotes the accumulation of
neurofibrillary bundles may appear in the brain. Cellular stress <italic>in
vitro </italic>can trigger the fragmentation of ApoE with production of the
toxic fragment. ApoE4 is more susceptible to cleavage, and expression of
truncated ApoE4 leads to AD-like neurodegeneration
[<xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R52">52</xref>].
</p>
<p>
Variations in the other genes involved in the cholesterol metabolism are also
risk factors for AD: for example, polymorphism of lipoprotein receptors (LRP1,
LRP10, SorLA, ApoER2) and transporters (ABCA1, ABCA7, clusterin) genes
[<xref ref-type="bibr" rid="R2">2</xref>]. LRP1 is involved in Aβ uptake and
elimination, and a decrease in its expression contributes to Aβ
accumulation. However, LRP1 increases the rate of endocytosis and directs APP
into the lysosomes, which may upregulate Aβ synthesis
[<xref ref-type="bibr" rid="R53">53</xref>]. A lower rate of endocytosis is typical
for LRP1B; therefore, LRP1B inhibits the formation of Aβ
[<xref ref-type="bibr" rid="R2">2</xref>]. SorLA/LR11, the level of which decreases in
the late forms of AD, interacts with APP monomers, preventing their
dimerization. This reduces APP cleavage by the γ- and β-secretases
that prefer to use APP dimers as a substrate [<xref ref-type="bibr" rid="R54">54</xref>].
LRP10 and SorLA enhance APP traffic to the Golgi complex,
where the secretases are less active [<xref ref-type="bibr" rid="R55">55</xref>].
Weak ABCA1 activity may contribute to AD, whereas its
overexpression reduces the accumulation of Aβ. ABCA1 deficiency leads to
the production of lipid-poor ApoE particles and a decrease in the amount of
ApoE (by ~ 80%); additionally, cholesterol esters accumulate in the peripheral
tissues [<xref ref-type="bibr" rid="R56">56</xref>].
</p>
<p>
<bold>Synaptic pathology in AD</bold>
</p>
<p>
Synaptic dysfunctions in AD represent the earliest events leading to cognitive
deficit. At the early stages of AD, a decrease in glutamatergic transmission
occurs in the cortex and hippocampus. The presynaptic events are the first to
change, and the impairment of postsynaptic processes is recorded later. Long
before the amyloid plaque formation, elimination of synapses and neuronal
death, the synthesis of the key proteins of exo-endocytotic machinery (SNAP-25,
synaptophysin, AP-2, AP-180, dynamin 1, synaptotagmin) decreases in the
prefrontal cortex, and the first cognitive defects are observed
[<xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R57">57</xref>-<xref ref-type="bibr" rid="R59">59</xref>].
Despite the variety of the effects of ApoE4 gene variants – changes in the APP
processing, decrease in Aβ clearance, synaptic plasticity interruptions
– there is a common pathway for ApoE4 action associated with changes in
endocytic recycling, probably through the reduction in the expression and
activity of endocytotic proteins [<xref ref-type="bibr" rid="R51">51</xref>].
In patients with AD, early endosomes are 32 times larger in volume and the
enlargement of endosomes begins before the manifestation of clinical symptoms
in Apo<italic>ε</italic>4 carriers [<xref ref-type="bibr" rid="R60">60</xref>].
Levetiracetam, acting on the SV2A protein of synaptic
vesicles, reverses the ApoE4-induced changes both in endosomal traffic and
Aβ processing [<xref ref-type="bibr" rid="R51">51</xref>].
</p>
<fig id="F3" orientation="portrait" position="float">
<label>Fig. 3</label>
<caption>
<p>
Pathways of amyloid peptide β (Aβ) action on synaptic transmission
and plasticity. Role of neuronal activity in Aβ accumulation. See text for
details.
</p>
</caption>
<graphic xlink:href="AN20758251-09-01-026-g003"></graphic>
</fig>
<p>
High neuronal activity increases the production of Aβ in normal and
pathological conditions (e.g., epilepsy). This is partly due to intense
synaptic vesicle endocytosis, whereby APP molecules are captured in endosomes
and are cleaved therein [<xref ref-type="bibr" rid="R61">61</xref>]. Also, soon
after a burst of synaptic activity the early gene <italic>Arc </italic>is
expressed and the Arc protein then increases the association of
γ-secretase with APP in endosomes [<xref ref-type="bibr" rid="R62">62</xref>].
During vesicular exocytosis, the generated Aβ is released into the synaptic cleft,
where it can regulate both neurotransmitter release and reception
(<italic><xref ref-type="fig" rid="F3">Fig. 3</xref></italic>).
Synaptic activity can reduce the intraneuronal accumulation of Aβ by increasing
the activity of neprilysin [<xref ref-type="bibr" rid="R63">63</xref>]. It is assumed
that APP and Aβ are elements of “physiological” feedback, which
controls synaptic transmission. Blocking Aβ production in young mice
reduces their performance in memory tests [<xref ref-type="bibr" rid="R64">64</xref>].
Overproduction of Aβ may be caused by
excessive/impaired synaptic activity. Individuals who carry mutations in
presenilin 1 show an increased activation of the hippocampus 15 years before
the onset of AD [<xref ref-type="bibr" rid="R65">65</xref>]. Enhanced
expression/activity of ryanodine receptors in nerve terminals, causing an
increased cytosolic Ca<sup>2+</sup> and exocytosis, may occur before
manifestations of histological and cognitive defects
[<xref ref-type="bibr" rid="R59">59</xref>]. ApoE4 changes the brain activity in the early period:
carriers of the <italic>Apoε4 </italic>allele have a higher activation of
the hippocampus at rest and when performing memory tests
[<xref ref-type="bibr" rid="R66">66</xref>]. ApoE4 interferes with reelin-dependent signaling, which
is involved in the migration, maturation, survival of neuronal cells, and
synaptic plasticity [<xref ref-type="bibr" rid="R2">2</xref>, <xref ref-type="bibr" rid="R8">8</xref>].
ApoE4 suppresses the effects of reelin,
because it decreases the number of available ApoE-receptors by preventing the
return of the receptors to the plasma membrane after the endocytosis induced by
binding to reelin and ApoE [<xref ref-type="bibr" rid="R50">50</xref>]. In
addition, reelin signaling becomes susceptible to the toxic action of Aβ.
Aβ via a mechanism involving mitochondrial dysfunction may activate
caspase 3, which (1) stimulates calcineurin (phosphatase PP2B) and (2) cleaves
the protein kinase Akt. Subsequently, PP2B dephosphorylates NMDA-receptors in
the sites for Fyn phosphorylation and loss of Akt leads to disinhibition of
GSK3β-kinase [<xref ref-type="bibr" rid="R67">67</xref>]. As a result, the
long-term potentiation in response to the activation of ApoE receptors by
reelin, which normally causes activation of Fyn and inhibition of
GSK3β-kinase, is suppressed in the hippocampus
[<xref ref-type="bibr" rid="R50">50</xref>]. Hyperactivity of GSK3β-kinase
may be a factor that contributes to excessive phosphorylation of the tau protein,
leading to the formation of neurofibrillary bundles, which disconnect from
microtubules and may diffuse throughout the neuron [<xref ref-type="bibr" rid="R8">8</xref>,
<xref ref-type="bibr" rid="R67">67</xref>].
</p>
<p>
<bold>The effects of the extra- and intracellular Aβ on synaptic
transmission</bold>
</p>
<p>
In synapses with weak activity, Aβ ([pM]) can activate presynaptic
α7-nicotinic cholinergic receptors, promoting an increase in cytosolic
Ca<sup>2+</sup> and the release of a neurotransmitter. In high doses, Aβ
([nM]) can enhance the internalization of postsynaptic NMDA- and AMPA-receptors and long-term depression
[<xref ref-type="bibr" rid="R58">58</xref>, <xref ref-type="bibr" rid="R68">68</xref>]. By blocking the reuptake of glutamate,
the elevated levels of Aβ lead to a decrease in the quantum size and a
persistent increase in glutamate concentration in the synaptic cleft. Thus,
postsynaptic NMDA-receptors become desensitized from the excessive stimulation
while presynaptic NMDA and metabotropic glutamate receptors are still
activated, causing long-term depression [<xref ref-type="bibr" rid="R57">57</xref>].
Aβ binds to presynaptically located P/Q-type calcium
channels leading to the inhibition of the neurotransmitter release
[<xref ref-type="bibr" rid="R69">69</xref>]. Aβ can form a Ca<sup>2+</sup>-pore,
the entry of Ca<sup>2+</sup> through which activates protease calpain that cuts
endocytotic protein dynamin 1 [<xref ref-type="bibr" rid="R70">70</xref>]. The
level of Cu<sup>2+</sup> increases in AD, Aβ in a complex with
Cu<sup>2+</sup> acquires the ability to convert cholesterol into
4-cholesten-3-one, and its concentration is increased in AD
[<xref ref-type="bibr" rid="R36">36</xref>]. The accumulation of 4-cholest-3- one can
inhibit synaptic Ca<sup>2+</sup>-ATP-ase, disrupt the stability of lipid rafts,
and depress neurotransmission [<xref ref-type="bibr" rid="R71">71</xref>].
Aβ may be involved in establishing the balance between silent and active
synapses: “low activity” synapses increase their “job”
in response to Aβ, while highly active synapses reduce it
(<italic><xref ref-type="fig" rid="F3">Fig. 3</xref></italic>).
It is worth noting that nerve terminals in old animals are more
susceptible to the negative effect of Aβ. These nerve terminals are
characterized by a smaller total synaptic vesicle pool, weak mitochondria
activity, and antioxidant capacity. Under these conditions, the inhibition of
synaptic vesicle recycling induced by Aβ is substantially lower in the
presence of exogenous antioxidants [<xref ref-type="bibr" rid="R72">72</xref>].
</p>
<p>
The severity of AD correlates with the presence of Aβ42 in neurons
(especially in the neocortex), and the suppression of neurotransmission
coincides with the accumulation of Aβ inside the nerve terminal, long
before the appearance of extracellular plaques
[<xref ref-type="bibr" rid="R28">28</xref>]. Aβ is trapped inside the endocytosed
vesicles, and the presence of Aβ42 in these vesicles activates casein kinase 2, which by
phosphorylation of dynamin and synaptophysin promotes the inhibition of
endocytosis and exhaustion of synaptic vesicle pools after the synaptic
activity [<xref ref-type="bibr" rid="R73">73</xref>]. Aβ absorbed into
vesicles directly interacts with synaptophysin and disrupts the formation of a
complex between synaptophysin and VAMP2, thereby increasing the number of
primed vesicles and enhancing exocytosis [<xref ref-type="bibr" rid="R74">74</xref>].
However, after intensive exocytosis, endocytosis is weak,
since the interaction of synaptophysin/VAMP2 is required for efficient
endocytosis. Chronic administration of Aβ in non-toxic concentrations
inhibits the glutamate release in the hippocampal nerve terminals by reducing
the size of readily releasable and recycling pools [<xref ref-type="bibr" rid="R75">75</xref>].
Perhaps that also can be attributed to the fact that
Aβ42 in endosomes are moved by axonal transport from nerve terminals to
cell bodies, where Aβ42 suppresses the expression of exocytotic and
endocytotic proteins: SNAP-25, synaptotagmin, synaptophysin, dynamin 1, and
amphiphysin 1 [<xref ref-type="bibr" rid="R57">57</xref>, <xref ref-type="bibr" rid="R58">58</xref>].
After endocytosis, Aβ can be directed towards
multivesicular bodies, where Aβ forms fibrils that perforate the
membranes, causing neuronal death. These fibrils subsequently form plaques
[<xref ref-type="bibr" rid="R76">76</xref>]. In general, many studies indicate
that endocytosis is the key event which is associated with the formation,
elimination, and toxicity of Aβ.
</p>
</sec>
<sec>
<title>PARKINSON’S DISEASE (PD)</title>
<p>
Parkinson’s disease (PD) is the second-most common neurodegenerative
disease, which is characterized by tremor, slowed movements, rigidity, and
cognitive impairment. As with AD, significantly fewer cases of PD are
associated with mutations in specific genes, such as α-synuclein, parkin,
LRRK2, PINK1, DJ-1, and ATP13A2. A peculiar feature of PD is the accumulation
of α-synuclein in neurons as a part of protein inclusions, the so-called
Lewy bodies. It affects dopaminergic neurons in the substantia nigra of the
midbrain. It is worth noting that contemporary studies have revealed that 60%
of patients with AD have deposits of α-synuclein in the amygdala, and that
some patients with PD have an accumulation of Aβ in the brain
[<xref ref-type="bibr" rid="R8">8</xref>, <xref ref-type="bibr" rid="R19">19</xref>,
<xref ref-type="bibr" rid="R30">30</xref>, <xref ref-type="bibr" rid="R77">77</xref>].
This suggests that specific pathways leading to the
development of PD or AD converge, causing the appearance of common signs.
</p>
<fig id="F4" orientation="portrait" position="float">
<label>Fig. 4</label>
<caption>
<p>
Relation between cholesterol, α-synuclein, and alterations in
presynaptic events with dopaminergic neuron dysfunction in Parkinson’s
disease. See text for details.
</p>
</caption>
<graphic xlink:href="AN20758251-09-01-026-g004"></graphic>
</fig>
<p>
The role of cholesterol in PD remains controversial
(<italic><xref ref-type="fig" rid="F4">Fig. 4</xref></italic>).
A study of lipid rafts isolated from the frontal cortex of subjects with
early-stage PD showed a decrease in polyunsaturated fatty acids without changes
in the content of cholesterol and sphingomyelin
[<xref ref-type="bibr" rid="R78">78</xref>]. However, α-synuclein comprises two
cholesterol-binding domains and membrane cholesterol affects its aggregation
[<xref ref-type="bibr" rid="R41">41</xref>]. Theoretically, synuclein can
disrupt the lipid raft integrity, by interacting with cholesterol
[<xref ref-type="bibr" rid="R1">1</xref>]. Cholesterol depletion (using
methyl-β-cyclodextrin) reduces the α-synuclein level in the membrane
and its accumulation in neuronal bodies and synapses. Statins inhibit the
aggregation of α-synuclein in a neuronal culture and the addition of
exogenous cholesterol increases α-synuclein aggregation, which suppresses
the growth of neurons [<xref ref-type="bibr" rid="R79">79</xref>]. Food
deprivation (on the model of 3D5-cells) causes the aggregation of
α-synuclein and apoptosis, which is associated with ER stress and SREBP1
activation, followed by an increase in cholesterol synthesis
[<xref ref-type="bibr" rid="R80">80</xref>]. In PD, the concentration of some
oxysterols increases in the brain in response to the overproduction of reactive
oxygen species [<xref ref-type="bibr" rid="R81">81</xref>]. A cholesterol-rich
diet reduces the ratio of 24OH-Ch : 27OH-Ch in the brain and increases the
level of α-synuclein in substantia nigra without altering the cerebral
cholesterol level. 27OH-Ch promotes and 24OH-Ch prevents an increase in
α-synuclein concentration in a SH-SY5Y human neuroblastoma cell line.
Moreover, 27OH-Ch exerts this effect through the activation of the LXβ-
receptors that bind to the promoter of the α-synuclein gene
[<xref ref-type="bibr" rid="R19">19</xref>].
</p>
<p>
Long before the neuronal death, the dopamine release is suppressed at the early
stage of PD. Mutations and duplications/triplication of the α-synuclein
gene causes PD with an early onset. α-Synuclein is concentrated in nerve
terminals and binds to synaptic vesicles. Normally, synuclein is important for
the clustering of vesicles in the proximity of the active zone, since it
simultaneously interacts with the synaptobrevin 2 of one vesicle and the
phospholipids of another vesicle, acting as a bridge. Mutation in the
α-synuclein gene may reduce its vesicle-clustering ability, and its
overexpression causes massive aggregation of synaptic vesicles, and eventually
both lead to a decrease in the size of the readily releasable pool
[<xref ref-type="bibr" rid="R82">82</xref>]. Overexpression of α-synuclein
contributes to its intensive interaction with the membranes of synaptic
vesicles and multivesicular bodies and disruption of their functioning
[<xref ref-type="bibr" rid="R83">83</xref>]. Overexpression of mutant α-synuclein
significantly alters the levels of the proteins involved in vesicular traffic
and exocytosis (reduced quantities of rabfilin 3A, syntaxin, kinesins 1A, 1B,
2A, increased levels of dynein, dynactin 1) in the substantia nigra and the
striatum [<xref ref-type="bibr" rid="R82">82</xref>]. A significant reduction
in transcript levels (dynamin 2, AP-2, syntaxin-2, VAMP A, VAMP 4), implicated
in vesicular cycling, was detected in the peripheral blood of patients at the
first stage of PD [<xref ref-type="bibr" rid="R84">84</xref>].
</p>
<p>
In the case of hereditary PD, associated with a mutation in the <italic>LRRK2
</italic>gene (kinase containing leucine rich repeat), the traffic of synaptic
vesicles is disrupted at the beginning of the disease. LRRK2 normally
phosphorylates endophilin, thereby inhibiting its association with the
membrane. At the same time excessive or insufficient activity of LRRK2 hinders
synaptic vesicle endocytosis [<xref ref-type="bibr" rid="R85">85</xref>]. The
juvenile form of PD is caused by mutations in the auxilin which participates in
the uncoating of synaptic clathrin-coated vesicles.
</p>
</sec>
<sec>
<title>AUTISM SPECTRUM DISORDERS (ASD)</title>
<p>
Autism spectrum disorders (ASD) are characterized by significant abnormalities
in social interaction, difficulty in communication, and stereotypical
behavioral patterns. These disorders may arise from genetic alterations,
prenatal exposure to viruses and toxins, and interactions of the mother’s
and fetus’ immune systems [<xref ref-type="bibr" rid="R30">30</xref>].
ASD are often associated with hereditary diseases, such as the Rett and fragile
X syndromes, neurofibromatosis type 1, tuberous sclerosis, phenylketonuria, and
the Smith-Opitz-Lemley syndrome.
</p>
<p>
Recently, new details have emerged concerning a relationship between
cholesterol metabolism and the pathogenesis of some ASD. The Rett syndrome,
which affects mainly women (1/10,000), is often associated with mutations in
the X-linked gene of methyl-CpG-binding protein 2 (MeCP2). MeCP2 interacts with
methylated DNA in the nucleus and recruits various transcription factors that
regulate gene transcription, including those involved in cholesterol
homeostasis. In the Rett syndrome, the levels of total cholesterol, the high-
and low-density lipoproteins are increased, and the expression of scavenger
receptor B1, responsible for the uptake of cholesterol, is reduced
[<xref ref-type="bibr" rid="R86">86</xref>]. Expression of the genes involved in
cholesterol metabolism was found to be slightly elevated in the brains of
one-month-old mice with a mutation in Mecp2/Y. At the age of 2 months, these
mice had an increased level of total cholesterol in the brain, but the
production of cholesterol was suppressed, probably due to the activation of a
negative feedback. As a result, by day 70 of postnatal development, the
cholesterol concentration returned to its normal range. Reducing the production
of cholesterol (mediated by a mutation in the gene
<italic>Sqle</italic>/squalene epoxidase or by statins) in the mutant Mecp2/Y
mice prevented a progression of the disease [<xref ref-type="bibr" rid="R87">87</xref>].
Treatment of women with the Rett syndrome with statins
also improves their mental state. Therefore, early abnormalities of cholesterol
metabolism in the Rett syndrome may contribute to the behavioral phenotype and
a decrease in the survival rate [<xref ref-type="bibr" rid="R86">86</xref>]. It
should be noted that statins also inhibit the synthesis of isoprenoid
intermediaries (farnesyl pyrophosphate and ubiquinones), affecting such protein
modifications as prenylation, which is important for the functioning of
signaling proteins, such as Ras [<xref ref-type="bibr" rid="R88">88</xref>].
</p>
<p>
Statins are effective in the fragile X syndrome and type 1 neurofibromatosis
[<xref ref-type="bibr" rid="R88">88</xref>]. The fragile X syndrome is one of
the known causes (1/4,000) of mental retardation and autism. This syndrome
occurs due to the expansion of CGG triplet repeats (greater than 200 repeats,
full mutation) in the promoter of the <italic>FMR1 </italic>gene (fragile X
mental retardation 1), which leads to hypermethylation and suppression of
<italic>FMR1 </italic>gene transcription [<xref ref-type="bibr" rid="R30">30</xref>].
Reduced production of the FMR protein (RNA-binding
protein that inhibits the translation induced by the activation of several
receptors in dendrites) enhances the synthesis of some proteins involved in
neurotransmission. Studies of animal models of the fragile X syndrome revealed
an abnormally high activity of group I metabotropic glutamate receptors
(mGR-I). Caveolin 1 and membrane cholesterol availability can regulate the
traffic and signaling of these receptors [<xref ref-type="bibr" rid="R42">42</xref>].
The signaling mediated by mGR-I is attenuated in the
neurons of mutant mice treated with statins. Additionally, such treatment
reduces the abnormally increased protein synthesis and long-term depression in
the hippocampus, audiogenic seizures, and visual cortex hyperexcitability.
</p>
<p>
ASD are closely related to synaptic dysfunction. Signs of ASD usually manifest
themselves in early childhood, when sensory experiences modify and tune the
excitation/inhibition balance; therefore, it is assumed that disruption of the
glutamate/GABAergic transmission ratio may contribute to ASD. The synaptic
theory of ASD began with the identification of a mutation leading to the
disease in the gene for neuroligin, a postsynaptic cell-adhesion molecule.
Then, it was found that many genes associated with predisposition to autism
encode synaptic proteins [<xref ref-type="bibr" rid="R90">90</xref>]. Mutations
in presynaptic cell-adhesion molecules, neurexins, inhibit synaptic vesicle
exocytosis in the hippocampus and cause social behavioral anomalies.
Dysfunction of the CASP2 protein, which regulates the release of electron-dense
granules with neuropeptides (neurotrophin-3, brain-derived neurotrophic factor)
and monoamines, increases the risk of autism [<xref ref-type="bibr" rid="R91">91</xref>].
Mutations in the <italic>Mecp2 </italic>gene reduce the
levels of synaptic proteins, including synapsins, and the vesicular glutamate
transporter. There is also a decrease in the expression of the
GABA-synthesizing enzyme GAD and the size of the neurotransmitter quantum in
GABA synapses [<xref ref-type="bibr" rid="R92">92</xref>]. The fragile X
syndrome involves downregulation of the GABA-A receptor α5- and
γ-subunits and tonic currents through receptors composed of these
subunits. Mice without reelin (normally expressed in cortical interneurons)
exhibit a ASD phenotype and decreased GABA spillover
[<xref ref-type="bibr" rid="R93">93</xref>]. Genetic polymorphism of exocytotic
protein SNAP-25, mutations in presynaptic synapsin 1, 2, and the active zone protein
RIMS3, which affect the neurotransmitter release, are associated with the probability
of ASD. Mutations in the postsynaptic proteins IL1RAPL1 and SynGAP1 involved in
synapse formation are also related to ASD [<xref ref-type="bibr" rid="R91">91</xref>].
</p>
</sec>
</body>
<back>
<ack>
<p>
This work was supported by a RFBR grant (№ 17-04-00046), and partly by
RFBR (№ 16-34-00127) and RNF (№14-15-00847).
</p>
</ack>
<glossary>
<def-list>
<title>Abbreviations</title>
<def-item>
<term id="G01">Aβ</term>
<def>
<p>amyloid peptide β</p>
</def>
</def-item>
<def-item>
<term id="G02">ABC</term>
<def>
<p>ATP-binding cassette transporters</p>
</def>
</def-item>
<def-item>
<term id="G03">ApoE</term>
<def>
<p>apolipoprotein E</p>
</def>
</def-item>
<def-item>
<term id="G04">AD</term>
<def>
<p>Alzheimer’s disease</p>
</def>
</def-item>
<def-item>
<term id="G05">PD</term>
<def>
<p>Parkinson’s disease</p>
</def>
</def-item>
<def-item>
<term id="G06">OH-Ch</term>
<def>
<p>hydroxycholesterol</p>
</def>
</def-item>
<def-item>
<term id="G07">BBB</term>
<def>
<p>blood-brain barrier</p>
</def>
</def-item>
<def-item>
<term id="G08">LRP</term>
<def>
<p>LDL-receptor related protein</p>
</def>
</def-item>
<def-item>
<term id="G09">LX-receptor</term>
<def>
<p>Liver X receptor</p>
</def>
</def-item>
<def-item>
<term id="G10">ASD</term>
<def>
<p>autism spectrum disorders</p>
</def>
</def-item>
<def-item>
<term id="G11">CYP46A1</term>
<def>
<p>cholesterol 24-hydroxylase</p>
</def>
</def-item>
<def-item>
<term id="G12">CYP7B1</term>
<def>
<p>oxysterol 7α-hydrolase</p>
</def>
</def-item>
<def-item>
<term id="G13">ER</term>
<def>
<p>endoplasmic reticulum</p>
</def>
</def-item>
</def-list>
</glossary>
<ref-list>
<title>References</title>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<source/>Acta Naturae.
          <year>2016</year>
<volume>8</volume>
<issue>1</issue>
<fpage>58</fpage>
<lpage>73</lpage>
<name>
<surname>Petrov</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Kasimov</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Zefirov</surname>
<given-names>A.L.</given-names>
</name>
<pub-id pub-id-type="pmid">27099785</pub-id>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="journal">
<source/>Nat. Rev. Neurosci.
          <year>2009</year>
<volume>10</volume>
<issue>5</issue>
<fpage>333</fpage>
<lpage>344</lpage>
<name>
<surname>Bu</surname>
<given-names>G.</given-names>
</name>
<pub-id pub-id-type="pmid">19339974</pub-id>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<source/>Nat. Rev. Neurosci.
          <year>2011</year>
<volume>12</volume>
<issue>5</issue>
<fpage>284</fpage>
<lpage>296</lpage>
<name>
<surname>Di</surname>
<given-names>Paolo G.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>T.W.</given-names>
</name>
<pub-id pub-id-type="pmid">21448224</pub-id>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<source/>Science.
          <year>2010</year>
<volume>330</volume>
<issue>6012</issue>
<fpage>1774</fpage>
<name>
<surname>Mawuenyega</surname>
<given-names>K.G.</given-names>
</name>
<name>
<surname>Sigurdson</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Ovod</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Munsell</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Kasten</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Morris</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Yarasheski</surname>
<given-names>K.E.</given-names>
</name>
<name>
<surname>Bateman</surname>
<given-names>R.J.</given-names>
</name>
<pub-id pub-id-type="pmid">21148344</pub-id>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<source/>Front. Aging Neurosci. 2014. V. 6. A.235.
          <year>2014</year>
<volume>6</volume>
<fpage>A.235</fpage>
<name>
<surname>Nalivaeva</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Belyaev</surname>
<given-names>N.D.</given-names>
</name>
<name>
<surname>Kerridge</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>A.J.</given-names>
</name>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<source/>Exp. Neurol.
          <year>1994</year>
<volume>126</volume>
<issue>1</issue>
<fpage>88</fpage>
<lpage>94</lpage>
<name>
<surname>Sparks</surname>
<given-names>D.L.</given-names>
</name>
<name>
<surname>Scheff</surname>
<given-names>S.W.</given-names>
</name>
<name>
<surname>Hunsaker</surname>
<given-names>J.C. 3rd.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Landers</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>D.R.</given-names>
</name>
<pub-id pub-id-type="pmid">8157129</pub-id>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<source/>Exp. Neurol.
          <year>2006</year>
<volume>200</volume>
<issue>2</issue>
<fpage>460</fpage>
<lpage>467</lpage>
<name>
<surname>Ghribi</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Larsen</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Schrag</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Herman</surname>
<given-names>M.M.</given-names>
</name>
<pub-id pub-id-type="pmid">16696972</pub-id>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<source/>EMBO Mol. Med.
          <year>2014</year>
<volume>6</volume>
<issue>7</issue>
<fpage>902</fpage>
<lpage>917</lpage>
<name>
<surname>Martin</surname>
<given-names>M.G.</given-names>
</name>
<name>
<surname>Ahmed</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Korovaichuk</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Venero</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Menchón</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Salas</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Munck</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Herreras</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Balschun</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Dotti</surname>
<given-names>C.G.</given-names>
</name>
<pub-id pub-id-type="pmid">24878762</pub-id>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<source/>JAMA Neurol.
          <year>2014</year>
<volume>71</volume>
<issue>2</issue>
<fpage>195</fpage>
<lpage>200</lpage>
<name>
<surname>Reed</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Villeneuve</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Mack</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>DeCarli</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Chui</surname>
<given-names>H.C.</given-names>
</name>
<name>
<surname>Jagust</surname>
<given-names>W.</given-names>
</name>
<pub-id pub-id-type="pmid">24378418</pub-id>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<source/>Brain Res.
          <year>2009</year>
<volume>1294</volume>
<fpage>202</fpage>
<lpage>210</lpage>
<name>
<surname>Kitaguchi</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Tomimoto</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Ihara</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Shibata</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Uemura</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kalaria</surname>
<given-names>R.N.</given-names>
</name>
<name>
<surname>Kihara</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Asada-Utsugi</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kinoshita</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>R.</given-names>
</name>
<pub-id pub-id-type="pmid">19646974</pub-id>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<source/>Biochimie.
          <year>2013</year>
<volume>95</volume>
<issue>3</issue>
<fpage>595</fpage>
<lpage>612</lpage>
<name>
<surname>Leoni</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Caccia</surname>
<given-names>C.</given-names>
</name>
<pub-id pub-id-type="pmid">23041502</pub-id>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<source/>J. Alzheimers Dis.
          <year>2012</year>
<volume>30</volume>
<issue>1</issue>
<fpage>53</fpage>
<lpage>61</lpage>
<name>
<surname>Hughes</surname>
<given-names>T.M.</given-names>
</name>
<name>
<surname>Kuller</surname>
<given-names>L.H.</given-names>
</name>
<name>
<surname>Lopez</surname>
<given-names>O.L.</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>J.T.</given-names>
</name>
<name>
<surname>Evans</surname>
<given-names>R.W.</given-names>
</name>
<name>
<surname>Sutton-Tyrrell</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rosano</surname>
<given-names>C.</given-names>
</name>
<pub-id pub-id-type="pmid">22377780</pub-id>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<source/>Molecular Therapy
          <year>2010</year>
<volume>18</volume>
<issue>1</issue>
<fpage>44</fpage>
<lpage>53</lpage>
<name>
<surname>Hudry</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>van Dam</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Kulik</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>De Deyn</surname>
<given-names>P.P.</given-names>
</name>
<name>
<surname>Stet</surname>
<given-names>F.S.</given-names>
</name>
<name>
<surname>Ahouansou</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Benraiss</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Delacourte</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bougnères</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Aubourg</surname>
<given-names>P.</given-names>
</name>
<pub-id pub-id-type="pmid">19654569</pub-id>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<source/>Proc. Natl. Acad. Sci. USA.
          <year>2002</year>
<volume>99</volume>
<issue>21</issue>
<fpage>13878</fpage>
<lpage>13883</lpage>
<name>
<surname>Wang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Schuster</surname>
<given-names>G.U.</given-names>
</name>
<name>
<surname>Hultenby</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Andersson</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Gustafsson</surname>
<given-names>J.A.</given-names>
</name>
<pub-id pub-id-type="pmid">12368482</pub-id>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<source/>J. Alzheimers Dis.
          <year>2014</year>
<volume>41</volume>
<issue>2</issue>
<fpage>535</fpage>
<lpage>549</lpage>
<name>
<surname>Fitz</surname>
<given-names>N.F.</given-names>
</name>
<name>
<surname>Castranio</surname>
<given-names>E.L.</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>A.Y.</given-names>
</name>
<name>
<surname>Kodali</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lefterov</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Koldamova</surname>
<given-names>R.</given-names>
</name>
<pub-id pub-id-type="pmid">24643138</pub-id>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<source/>J. Neurochem.
          <year>2013</year>
<volume>126</volume>
<issue>1</issue>
<fpage>93</fpage>
<lpage>101</lpage>
<name>
<surname>Matsuda</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Nagao</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Matsuo</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kioka</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Ueda</surname>
<given-names>K.</given-names>
</name>
<pub-id pub-id-type="pmid">23600914</pub-id>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<source/>Biochem. Biophys. Res. Commun.
          <year>2014</year>
<volume>446</volume>
<issue>3</issue>
<fpage>687</fpage>
<lpage>691</lpage>
<name>
<surname>Gosselet</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Saint-Pol</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Fenart</surname>
<given-names>L.</given-names>
</name>
<pub-id pub-id-type="pmid">24275140</pub-id>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<source/>J. Lipid Res.
          <year>2004</year>
<volume>45</volume>
<issue>1</issue>
<fpage>186</fpage>
<lpage>193</lpage>
<name>
<surname>Heverin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bogdanovic</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lütjohann</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Bayer</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pikuleva</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Bretillon</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Diczfalusy</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Winblad</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Björkhem</surname>
<given-names>I.</given-names>
</name>
<pub-id pub-id-type="pmid">14523054</pub-id>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="journal">
<source/>Exp. Gerontol.
          <year>2014</year>
<elocation-id> pii: S0531- 5565(14)00270-8.</elocation-id>
<name>
<surname>Marwarha</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ghribi</surname>
<given-names>O.</given-names>
</name>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<source/>Neurobiol. Aging.
          <year>1992</year>
<volume>13</volume>
<issue>3</issue>
<fpage>413</fpage>
<lpage>419</lpage>
<name>
<surname>Mason</surname>
<given-names>R.P.</given-names>
</name>
<name>
<surname>Shoemaker</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Shajenko</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chambers</surname>
<given-names>T.E.</given-names>
</name>
<name>
<surname>Herbette</surname>
<given-names>L.G.</given-names>
</name>
<pub-id pub-id-type="pmid">1625771</pub-id>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<source/>J. Neurochem.
          <year>2005</year>
<volume>92</volume>
<issue>1</issue>
<fpage>171</fpage>
<lpage>182</lpage>
<name>
<surname>Molander-Melin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Blennow</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Bogdanovic</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Dellheden</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Månsson</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Fredman</surname>
<given-names>P.</given-names>
</name>
<pub-id pub-id-type="pmid">15606906</pub-id>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<source/>J. Cell Biol.
          <year>2004</year>
<volume>167</volume>
<issue>5</issue>
<fpage>953</fpage>
<lpage>960</lpage>
<name>
<surname>Abad-Rodriguez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ledesma</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Craessaerts</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Perga</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Medina</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Delacourte</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dingwall</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>De Strooper</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Dotti</surname>
<given-names>C.G.</given-names>
</name>
<pub-id pub-id-type="pmid">15583033</pub-id>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<source/>Neurobiol. Aging.
          <year>2007</year>
<volume>28</volume>
<issue>1</issue>
<fpage>8</fpage>
<lpage>17</lpage>
<name>
<surname>Gylys</surname>
<given-names>K.H.</given-names>
</name>
<name>
<surname>Fein</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Miller</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Cole</surname>
<given-names>G.M.</given-names>
</name>
<pub-id pub-id-type="pmid">16332401</pub-id>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<source/>EMBO Mol. Med.
          <year>2013</year>
<volume>5</volume>
<issue>4</issue>
<fpage>608</fpage>
<lpage>625</lpage>
<name>
<surname>Pierrot</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Tyteca</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>D’auria</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dewachter</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Gailly</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Hendrickx</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Tasiaux</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Haylani</surname>
<given-names>L.E.</given-names>
</name>
<name>
<surname>Muls</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>N’kuli</surname>
<given-names>F.</given-names>
</name>
<pub-id pub-id-type="pmid">23554170</pub-id>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<source/>J. Alzheimers Dis.
          <year>2014</year>
<volume>41</volume>
<issue>1</issue>
<fpage>289</fpage>
<lpage>300</lpage>
<name>
<surname>Evangelisti</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Zampagni</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Cascella</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Becatti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Fiorillo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Caselli</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Bagnoli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nacmias</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Cecchi</surname>
<given-names>C.</given-names>
</name>
<pub-id pub-id-type="pmid">24614900</pub-id>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<source/>EMBO J.
          <year>2012</year>
<volume>31</volume>
<issue>7</issue>
<fpage>1764</fpage>
<lpage>1773</lpage>
<name>
<surname>Sodero</surname>
<given-names>A.O.</given-names>
</name>
<name>
<surname>Vriens</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Stegner</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Brachet</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Pallotto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sassoè-Pognetto</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Brouwers</surname>
<given-names>J.F.</given-names>
</name>
<name>
<surname>Helms</surname>
<given-names>J.B.</given-names>
</name>
<name>
<surname>Nieswandt</surname>
<given-names>B.</given-names>
</name>
<pub-id pub-id-type="pmid">22343944</pub-id>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<source/>Neurobiol. Aging.
          <year>2011</year>
<volume>32</volume>
<issue>6</issue>
<fpage>1043</fpage>
<lpage>1053</lpage>
<name>
<surname>Sodero</surname>
<given-names>A.O.</given-names>
</name>
<name>
<surname>Weissmann</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Ledesma</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Dotti</surname>
<given-names>C.G.</given-names>
</name>
<pub-id pub-id-type="pmid">20663588</pub-id>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<source/>J. Alzheimers Dis.
          <year>2007</year>
<volume>11</volume>
<issue>1</issue>
<fpage>53</fpage>
<lpage>59</lpage>
<name>
<surname>Gómez-Ramos</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Asunción Morán</surname>
<given-names>M.</given-names>
</name>
<pub-id pub-id-type="pmid">17361035</pub-id>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<source/>Proc. Natl. Acad. Sci. USA.
          <year>2010</year>
<volume>107</volume>
<fpage>3081</fpage>
<lpage>3086</lpage>
<name>
<surname>Bryleva</surname>
<given-names>E.Y.</given-names>
</name>
<name>
<surname>Rogers</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>C.C.</given-names>
</name>
<name>
<surname>Buen</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>B.T.</given-names>
</name>
<name>
<surname>Rousselet</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Seidah</surname>
<given-names>N.G.</given-names>
</name>
<name>
<surname>Oddo</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>LaFerla</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Spencer</surname>
<given-names>T.A.</given-names>
</name>
<pub-id pub-id-type="pmid">20133765</pub-id>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<source/>Front Physiol.
          <year>2013</year>
<volume>3</volume>
<fpage>1</fpage>
<lpage>12</lpage>
<name>
<surname>Anchisi</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Dessì</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Pani</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mandas</surname>
<given-names>A.</given-names>
</name>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<source/>BMC Geriatrics. 2014. V. 14. A.
          <year>2014</year>
<volume>14</volume>
<fpage>A.36</fpage>
<name>
<surname>Lathe</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Sapronova</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Kotelevtsev</surname>
<given-names>Y.</given-names>
</name>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<source/>Int. J. Alzheimers. Dis.
          <year>2011</year>
<fpage>603052</fpage>
<name>
<surname>Rushworth</surname>
<given-names>J.V.</given-names>
</name>
<name>
<surname>Hooper</surname>
<given-names>N.M.</given-names>
</name>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<source/>Int. J. Alzheimers Dis.
          <year>2011</year>
<volume>2011</volume>
<fpage>956104</fpage>
<name>
<surname>Matsuzaki</surname>
<given-names>K.</given-names>
</name>
<pub-id pub-id-type="pmid">21318142</pub-id>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<source/>Science.
          <year>2012</year>
<volume>336</volume>
<fpage>1168</fpage>
<lpage>1171</lpage>
<name>
<surname>Barrett</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>van Horn</surname>
<given-names>W.D.</given-names>
</name>
<name>
<surname>Hustedt</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Schafer</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Hadziselimovic</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Beel</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Sanders</surname>
<given-names>C.R.</given-names>
</name>
<pub-id pub-id-type="pmid">22654059</pub-id>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<source/>FASEB J.
          <year>2012</year>
<volume>26</volume>
<issue>4</issue>
<fpage>1672</fpage>
<lpage>1681</lpage>
<name>
<surname>Woo</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Roh</surname>
<given-names>S.E.</given-names>
</name>
<name>
<surname>Lakshmana</surname>
<given-names>M.K.</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>D.E.</given-names>
</name>
<pub-id pub-id-type="pmid">22223749</pub-id>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<source/>J. Clin. Invest.
          <year>2005</year>
<volume>115</volume>
<issue>9</issue>
<fpage>2556</fpage>
<lpage>2563</lpage>
<name>
<surname>Puglielli</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Friedlich</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Setchell</surname>
<given-names>K.D.</given-names>
</name>
<name>
<surname>Nagano</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Opazo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Cherny</surname>
<given-names>R.A.</given-names>
</name>
<name>
<surname>Barnham</surname>
<given-names>K.J.</given-names>
</name>
<name>
<surname>Wade</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Melov</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kovacs</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Bush</surname>
<given-names>A.I.</given-names>
</name>
<pub-id pub-id-type="pmid">16127459</pub-id>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<source/>Neurobiol. Aging.
          <year>2011</year>
<volume>32</volume>
<issue>2</issue>
<fpage>210</fpage>
<lpage>222</lpage>
<name>
<surname>Pensalfini</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Zampagni</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Liguri</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Becatti</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Evangelisti</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Fiorillo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Bagnoli</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cellini</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Nacmias</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Sorbi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cecchi</surname>
<given-names>C.</given-names>
</name>
<pub-id pub-id-type="pmid">19297055</pub-id>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<source/>J. Biol. Chem.
          <year>2013</year>
<volume>288</volume>
<issue>13</issue>
<fpage>8935</fpage>
<lpage>8951</lpage>
<name>
<surname>Rushworth</surname>
<given-names>J.V.</given-names>
</name>
<name>
<surname>Griffiths</surname>
<given-names>H.H.</given-names>
</name>
<name>
<surname>Watt</surname>
<given-names>N.T.</given-names>
</name>
<name>
<surname>Hooper</surname>
<given-names>N.M.</given-names>
</name>
<pub-id pub-id-type="pmid">23386614</pub-id>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<source/>EMBO Rep.
          <year>2003</year>
<volume>4</volume>
<issue>12</issue>
<fpage>1190</fpage>
<lpage>1196</lpage>
<name>
<surname>Ledesma</surname>
<given-names>M.D.</given-names>
</name>
<name>
<surname>Abad-Rodriguez</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Galvan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Biondi</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Navarro</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Delacourte</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dingwall</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Dotti</surname>
<given-names>C.G.</given-names>
</name>
<pub-id pub-id-type="pmid">14618158</pub-id>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<source/>J. Biol. Chem.
          <year>2009</year>
<volume>284</volume>
<issue>49</issue>
<fpage>34433</fpage>
<lpage>34443</lpage>
<name>
<surname>Sarajärvi</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Haapasalo</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Viswanathan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Mäkinen</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Laitinen</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Soininen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hiltunen</surname>
<given-names>M.</given-names>
</name>
<pub-id pub-id-type="pmid">19815556</pub-id>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<source/>PLoS One.
          <year>2010</year>
<volume>5</volume>
<issue>12</issue>
<elocation-id>e15697</elocation-id>
<name>
<surname>Head</surname>
<given-names>B.P.</given-names>
</name>
<name>
<surname>Peart</surname>
<given-names>J.N.</given-names>
</name>
<name>
<surname>Panneerselvam</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Yokoyama</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Pearn</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Niesman</surname>
<given-names>I.R.</given-names>
</name>
<name>
<surname>Bonds</surname>
<given-names>J.A.</given-names>
</name>
<name>
<surname>Schilling</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Miyanohara</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Headrick</surname>
<given-names>J.</given-names>
</name>
<pub-id pub-id-type="pmid">21203469</pub-id>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<source/>Front. Physiol.
          <year>2012</year>
<volume>3</volume>
<fpage>393</fpage>
<name>
<surname>Stary</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Tsutsumi</surname>
<given-names>Y.M.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Head</surname>
<given-names>B.P.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>H.H.</given-names>
</name>
<name>
<surname>Roth</surname>
<given-names>D.M.</given-names>
</name>
<pub-id pub-id-type="pmid">23060817</pub-id>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="journal">
<source/>Neurology.
          <year>2011</year>
<volume>77</volume>
<fpage>556</fpage>
<lpage>563</lpage>
<name>
<surname>Sano</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bell</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Galasko</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Galvin</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>R.G.</given-names>
</name>
<name>
<surname>van Dyck</surname>
<given-names>C.H.</given-names>
</name>
<name>
<surname>Aisen</surname>
<given-names>P.S.</given-names>
</name>
<pub-id pub-id-type="pmid">21795660</pub-id>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="journal">
<source/>Behav. Brain Res.
          <year>2014</year>
<volume>267</volume>
<fpage>6</fpage>
<lpage>11</lpage>
<name>
<surname>Schilling</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Cui</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Godoy</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Risbrough</surname>
<given-names>V.B.</given-names>
</name>
<name>
<surname>Niesman</surname>
<given-names>I.R.</given-names>
</name>
<name>
<surname>Roth</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Drummond</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>H.H.</given-names>
</name>
<name>
<surname>Zemljic-Harpf</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Head</surname>
<given-names>B.P.</given-names>
</name>
<pub-id pub-id-type="pmid">24657594</pub-id>
</element-citation>
</ref>
<ref id="R45">
<label>45</label>
<element-citation publication-type="journal">
<source/>J. Neurosci.
          <year>2013</year>
<volume>33</volume>
<issue>41</issue>
<fpage>16072</fpage>
<lpage>16087</lpage>
<name>
<surname>Burg</surname>
<given-names>V.K.</given-names>
</name>
<name>
<surname>Grimm</surname>
<given-names>H.S.</given-names>
</name>
<name>
<surname>Rothhaar</surname>
<given-names>T.L.</given-names>
</name>
<name>
<surname>Grösgen</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Hundsdörfer</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Haupenthal</surname>
<given-names>V.J.</given-names>
</name>
<name>
<surname>Zimmer</surname>
<given-names>V.C.</given-names>
</name>
<name>
<surname>Mett</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Weingärtner</surname>
<given-names>O.</given-names>
</name>
<name>
<surname>Laufs</surname>
<given-names>U.</given-names>
</name>
<pub-id pub-id-type="pmid">24107941</pub-id>
</element-citation>
</ref>
<ref id="R46">
<label>46</label>
<element-citation publication-type="journal">
<source/>Disease Models Mechanisms.
          <year>2012</year>
<volume>5</volume>
<fpage>746</fpage>
<lpage>755</lpage>
<name>
<surname>Vance</surname>
<given-names>J.E.</given-names>
</name>
<pub-id pub-id-type="pmid">23065638</pub-id>
</element-citation>
</ref>
<ref id="R47">
<label>47</label>
<element-citation publication-type="journal">
<source/>Neuron.
          <year>2014</year>
<volume>83</volume>
<issue>4</issue>
<fpage>771</fpage>
<lpage>787</lpage>
<name>
<surname>Lane-Donovan</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Philips</surname>
<given-names>G.T.</given-names>
</name>
<name>
<surname>Herz</surname>
<given-names>J.</given-names>
</name>
<pub-id pub-id-type="pmid">25144875</pub-id>
</element-citation>
</ref>
<ref id="R48">
<label>48</label>
<element-citation publication-type="journal">
<source/>Science.
          <year>2012</year>
<volume>335</volume>
<fpage>1503</fpage>
<lpage>1506</lpage>
<name>
<surname>Cramer</surname>
<given-names>P.E.</given-names>
</name>
<name>
<surname>Cirrito</surname>
<given-names>J.R.</given-names>
</name>
<name>
<surname>Wesson</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>C.Y.</given-names>
</name>
<name>
<surname>Karlo</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Zinn</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Casali</surname>
<given-names>B.T.</given-names>
</name>
<name>
<surname>Restivo</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Goebel</surname>
<given-names>W.D.</given-names>
</name>
<name>
<surname>James</surname>
<given-names>M.J.</given-names>
</name>
<pub-id pub-id-type="pmid">22323736</pub-id>
</element-citation>
</ref>
<ref id="R49">
<label>49</label>
<element-citation publication-type="journal">
<source/>Biol. Pharm. Bull.
          <year>2011</year>
<volume>34</volume>
<issue>4</issue>
<fpage>453</fpage>
<lpage>461</lpage>
<name>
<surname>Hayashi</surname>
<given-names>H.</given-names>
</name>
<pub-id pub-id-type="pmid">21467629</pub-id>
</element-citation>
</ref>
<ref id="R50">
<label>50</label>
<element-citation publication-type="journal">
<source/>Proc. Natl. Acad. Sci. USA.
          <year>2009</year>
<volume>106</volume>
<issue>37</issue>
<fpage>15938</fpage>
<lpage>15943</lpage>
<name>
<surname>Durakoglugil</surname>
<given-names>M.S.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>White</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Kavalali</surname>
<given-names>E.T.</given-names>
</name>
<name>
<surname>Herz</surname>
<given-names>J.</given-names>
</name>
<pub-id pub-id-type="pmid">19805234</pub-id>
</element-citation>
</ref>
<ref id="R51">
<label>51</label>
<element-citation publication-type="journal">
<source/>Nature
          <year>2013</year>
<volume>500</volume>
<issue>7460</issue>
<fpage>45</fpage>
<lpage>50</lpage>
<name>
<surname>Rhinn</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Fujita</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Qiang</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J.H.</given-names>
</name>
<name>
<surname>Abeliovich</surname>
<given-names>A.</given-names>
</name>
<pub-id pub-id-type="pmid">23883936</pub-id>
</element-citation>
</ref>
<ref id="R52">
<label>52</label>
<element-citation publication-type="journal">
<source/>Proc. Natl. Acad. Sci. USA.
          <year>2003</year>
<volume>100</volume>
<issue>19</issue>
<fpage>10966</fpage>
<lpage>10971</lpage>
<name>
<surname>Harris</surname>
<given-names>F.M.</given-names>
</name>
<name>
<surname>Brecht</surname>
<given-names>W.J.</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Tesseur</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Kekonius</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Wyss-Coray</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Fish</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Masliah</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Hopkins</surname>
<given-names>P.C.</given-names>
</name>
<name>
<surname>Scearce-Levie</surname>
<given-names>K.</given-names>
</name>
<pub-id pub-id-type="pmid">12939405</pub-id>
</element-citation>
</ref>
<ref id="R53">
<label>53</label>
<element-citation publication-type="journal">
<source/>J. Neurosci.
          <year>2010</year>
<volume>30</volume>
<issue>50</issue>
<fpage>17068</fpage>
<lpage>17078</lpage>
<name>
<surname>Liu</surname>
<given-names>Q.</given-names>
</name>
<name>
<surname>Trotter</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>M.M.</given-names>
</name>
<name>
<surname>Cheng</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Bao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Weeber</surname>
<given-names>E.J.</given-names>
</name>
<name>
<surname>Bu</surname>
<given-names>G.</given-names>
</name>
<pub-id pub-id-type="pmid">21159977</pub-id>
</element-citation>
</ref>
<ref id="R54">
<label>54</label>
<element-citation publication-type="journal">
<source/>EMBO J.
          <year>2012</year>
<volume>31</volume>
<issue>1</issue>
<fpage>187</fpage>
<lpage>200</lpage>
<name>
<surname>Schmidt</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Baum</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Lao</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Rateitschak</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Schmitz</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Teichmann</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wiesner</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Petersen</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Nykjaer</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Wolf</surname>
<given-names>J.</given-names>
</name>
<pub-id pub-id-type="pmid">21989385</pub-id>
</element-citation>
</ref>
<ref id="R55">
<label>55</label>
<element-citation publication-type="journal">
<source/>Mol. Neurodegener.
          <year>2012</year>
<volume>7</volume>
<fpage>31</fpage>
<name>
<surname>Brodeur</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Thériault</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Lessard-Beaudoin</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Marcil</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Dahan</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lavoie</surname>
<given-names>C.</given-names>
</name>
<pub-id pub-id-type="pmid">22734645</pub-id>
</element-citation>
</ref>
<ref id="R56">
<label>56</label>
<element-citation publication-type="journal">
<source/>Neurobiol. Dis.
          <year>2013</year>
<volume>54</volume>
<fpage>445</fpage>
<lpage>455</lpage>
<name>
<surname>Karasinska</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>de Haan</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Franciosi</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Ruddle</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Kruit</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Stukas</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lütjohann</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Gutmann</surname>
<given-names>D.H.</given-names>
</name>
<name>
<surname>Wellington</surname>
<given-names>C.L.</given-names>
</name>
<pub-id pub-id-type="pmid">23376685</pub-id>
</element-citation>
</ref>
<ref id="R57">
<label>57</label>
<element-citation publication-type="journal">
<source/>Nat. Neurosci.
          <year>2010</year>
<volume>13</volume>
<issue>7</issue>
<fpage>812</fpage>
<lpage>818</lpage>
<name>
<surname>Palop</surname>
<given-names>J.J.</given-names>
</name>
<name>
<surname>Mucke</surname>
<given-names>L.</given-names>
</name>
<pub-id pub-id-type="pmid">20581818</pub-id>
</element-citation>
</ref>
<ref id="R58">
<label>58</label>
<element-citation publication-type="journal">
<source/>Cold Spring Harb. Perspect. Biol.
          <year>2012</year>
<volume>4</volume>
<issue>5</issue>
<elocation-id>pii: a005777</elocation-id>
<name>
<surname>Sheng</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Sabatini</surname>
<given-names>B.L.</given-names>
</name>
<name>
<surname>Südhof</surname>
<given-names>T.C.</given-names>
</name>
</element-citation>
</ref>
<ref id="R59">
<label>59</label>
<element-citation publication-type="journal">
<source/>J. Neurosci.
          <year>2012</year>
<volume>32</volume>
<issue>24</issue>
<fpage>8341</fpage>
<lpage>8353</lpage>
<name>
<surname>Chakroborty</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Schneider</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Jacobson</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Molgó</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Stutzmann</surname>
<given-names>G.E.</given-names>
</name>
<pub-id pub-id-type="pmid">22699914</pub-id>
</element-citation>
</ref>
<ref id="R60">
<label>60</label>
<element-citation publication-type="journal">
<source/>Nature
          <year>2012</year>
<volume>482</volume>
<issue>7384</issue>
<fpage>216</fpage>
<lpage>220</lpage>
<name>
<surname>Israel</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>S.H.</given-names>
</name>
<name>
<surname>Bardy</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Reyna</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>Mu</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Herrera</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Hefferan</surname>
<given-names>M.P.</given-names>
</name>
<name>
<surname>van Gorp</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Nazor</surname>
<given-names>K.L.</given-names>
</name>
<name>
<surname>Boscolo</surname>
<given-names>F.S.</given-names>
</name>
<pub-id pub-id-type="pmid">22278060</pub-id>
</element-citation>
</ref>
<ref id="R61">
<label>61</label>
<element-citation publication-type="journal">
<source/>J. Neurosci.
          <year>1997</year>
<volume>17</volume>
<issue>16</issue>
<fpage>6142</fpage>
<lpage>6151</lpage>
<name>
<surname>Cataldo</surname>
<given-names>A.M.</given-names>
</name>
<name>
<surname>Barnett</surname>
<given-names>J.L.</given-names>
</name>
<name>
<surname>Pieroni</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Nixon</surname>
<given-names>R.A.</given-names>
</name>
<pub-id pub-id-type="pmid">9236226</pub-id>
</element-citation>
</ref>
<ref id="R62">
<label>62</label>
<element-citation publication-type="journal">
<source/>Cell.
          <year>2011</year>
<volume>147</volume>
<issue>3</issue>
<fpage>615</fpage>
<lpage>628</lpage>
<name>
<surname>Wu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Petralia</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Kurushima</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Jung</surname>
<given-names>M.Y.</given-names>
</name>
<name>
<surname>Volk</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Chowdhury</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Shepherd</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Dehoff</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Y.</given-names>
</name>
<pub-id pub-id-type="pmid">22036569</pub-id>
</element-citation>
</ref>
<ref id="R63">
<label>63</label>
<element-citation publication-type="journal">
<source/>J. Neurosci.
          <year>2009</year>
<volume>29</volume>
<issue>31</issue>
<fpage>9704</fpage>
<lpage>9713</lpage>
<name>
<surname>Tampellini</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Rahman</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Gallo</surname>
<given-names>E.F.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Z.</given-names>
</name>
<name>
<surname>Dumont</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Capetillo-Zarate</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Ma</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Nanus</surname>
<given-names>D.M.</given-names>
</name>
<pub-id pub-id-type="pmid">19657023</pub-id>
</element-citation>
</ref>
<ref id="R64">
<label>64</label>
<element-citation publication-type="journal">
<source/>Ann. Neurol.
          <year>2011</year>
<volume>69</volume>
<issue>5</issue>
<fpage>819</fpage>
<lpage>830</lpage>
<name>
<surname>Puzzo</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Privitera</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Fa’</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Staniszewski</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Aziz</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Sakurai</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Ribe</surname>
<given-names>E.M.</given-names>
</name>
<name>
<surname>Troy</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Mercken</surname>
<given-names>M.</given-names>
</name>
<pub-id pub-id-type="pmid">21472769</pub-id>
</element-citation>
</ref>
<ref id="R65">
<label>65</label>
<element-citation publication-type="journal">
<source/>Ann. Neurol.
          <year>2010</year>
<volume>68</volume>
<issue>6</issue>
<fpage>865</fpage>
<lpage>875</lpage>
<name>
<surname>Quiroz</surname>
<given-names>Y.T.</given-names>
</name>
<name>
<surname>Budson</surname>
<given-names>A.E.</given-names>
</name>
<name>
<surname>Celone</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Ruiz</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Newmark</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Castrillón</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Lopera</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Stern</surname>
<given-names>C.E.</given-names>
</name>
<pub-id pub-id-type="pmid">21194156</pub-id>
</element-citation>
</ref>
<ref id="R66">
<label>66</label>
<element-citation publication-type="journal">
<source/>JAMA Neurol.
          <year>2014</year>
<volume>71</volume>
<issue>1</issue>
<fpage>11</fpage>
<lpage>22</lpage>
<name>
<surname>Dean</surname>
<given-names>D.C. 3rd1.</given-names>
</name>
<name>
<surname>Jerskey</surname>
<given-names>B.A.</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Protas</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Thiyyagura</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Roontiva</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>O’Muircheartaigh</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Dirks</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Waskiewicz</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Lehman</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Siniard</surname>
<given-names>A.L.</given-names>
</name>
<pub-id pub-id-type="pmid">24276092</pub-id>
</element-citation>
</ref>
<ref id="R67">
<label>67</label>
<element-citation publication-type="journal">
<source/>Nat. Neurosci.
          <year>2011</year>
<volume>14</volume>
<issue>5</issue>
<fpage>545</fpage>
<lpage>547</lpage>
<name>
<surname>Jo</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Whitcomb</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Olsen</surname>
<given-names>K.M.</given-names>
</name>
<name>
<surname>Kerrigan</surname>
<given-names>T.L.</given-names>
</name>
<name>
<surname>Lo</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Bru-Mercier</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Dickinson</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Scullion</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Sheng</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Collingridge</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>K.</given-names>
</name>
<pub-id pub-id-type="pmid">21441921</pub-id>
</element-citation>
</ref>
<ref id="R68">
<label>68</label>
<element-citation publication-type="journal">
<source/>Acta Naturae.
          <year>2010</year>
<volume>2</volume>
<issue>1(4)</issue>
<fpage>72</fpage>
<lpage>80</lpage>
<name>
<surname>Bezprozvanny</surname>
<given-names>I.B.</given-names>
</name>
</element-citation>
</ref>
<ref id="R69">
<label>69</label>
<element-citation publication-type="journal">
<source/>J. Neurosci.
          <year>2008</year>
<volume>28</volume>
<issue>4</issue>
<fpage>788</fpage>
<lpage>797</lpage>
<name>
<surname>Nimmrich</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Grimm</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Draguhn</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Barghorn</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Lehmann</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Schoemaker</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Hillen</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Gross</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ebert</surname>
<given-names>U.</given-names>
</name>
<name>
<surname>Bruehl</surname>
<given-names>C.</given-names>
</name>
<pub-id pub-id-type="pmid">18216187</pub-id>
</element-citation>
</ref>
<ref id="R70">
<label>70</label>
<element-citation publication-type="journal">
<source/>Neurochem. Int.
          <year>2008</year>
<volume>53</volume>
<issue>3-4</issue>
<fpage>79</fpage>
<lpage>88</lpage>
<name>
<surname>Sinjoanu</surname>
<given-names>R.C.</given-names>
</name>
<name>
<surname>Kleinschmidt</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Bitner</surname>
<given-names>R.S.</given-names>
</name>
<name>
<surname>Brioni</surname>
<given-names>J.D.</given-names>
</name>
<name>
<surname>Moeller</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Ferreira</surname>
<given-names>A.</given-names>
</name>
<pub-id pub-id-type="pmid">18590784</pub-id>
</element-citation>
</ref>
<ref id="R71">
<label>71</label>
<element-citation publication-type="journal">
<source/>Biochim. Biophys. Acta.
          <year>2015</year>
<volume>1851</volume>
<issue>5</issue>
<fpage>674</fpage>
<lpage>685</lpage>
<name>
<surname>Kasimov</surname>
<given-names>M.R.</given-names>
</name>
<name>
<surname>Giniatullin</surname>
<given-names>A.R.</given-names>
</name>
<name>
<surname>Zefirov</surname>
<given-names>A.L.</given-names>
</name>
<name>
<surname>Petrov</surname>
<given-names>A.M.</given-names>
</name>
<pub-id pub-id-type="pmid">25725358</pub-id>
</element-citation>
</ref>
<ref id="R72">
<label>72</label>
<element-citation publication-type="journal">
<source/>Curr. Alzheimer Res.
          <year>2013</year>
<volume>10</volume>
<issue>3</issue>
<fpage>324</fpage>
<lpage>331</lpage>
<name>
<surname>Quiroz-Baez</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Flores-Domínguez</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Arias</surname>
<given-names>C.</given-names>
</name>
<pub-id pub-id-type="pmid">23305068</pub-id>
</element-citation>
</ref>
<ref id="R73">
<label>73</label>
<element-citation publication-type="journal">
<source/>Proc. Natl. Acad. Sci. USA.
          <year>2009</year>
<volume>106</volume>
<issue>14</issue>
<fpage>5901</fpage>
<lpage>5906</lpage>
<name>
<surname>Moreno</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Pigino</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Hernandez</surname>
<given-names>A.I.</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Moreira</surname>
<given-names>J.E.</given-names>
</name>
<name>
<surname>Sugimori</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Llinás</surname>
<given-names>R.R.</given-names>
</name>
<pub-id pub-id-type="pmid">19304802</pub-id>
</element-citation>
</ref>
<ref id="R74">
<label>74</label>
<element-citation publication-type="journal">
<source/>PLoS One.
          <year>2012</year>
<volume>7</volume>
<issue>8</issue>
<elocation-id>e43201</elocation-id>
<name>
<surname>Russell</surname>
<given-names>C.L.</given-names>
</name>
<name>
<surname>Semerdjieva</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Empson</surname>
<given-names>R.M.</given-names>
</name>
<name>
<surname>Austen</surname>
<given-names>B.M.</given-names>
</name>
<name>
<surname>Beesley</surname>
<given-names>P.W.</given-names>
</name>
<name>
<surname>Alifragis</surname>
<given-names>P.</given-names>
</name>
<pub-id pub-id-type="pmid">22905234</pub-id>
</element-citation>
</ref>
<ref id="R75">
<label>75</label>
<element-citation publication-type="journal">
<source/>J. Biol. Chem.
          <year>2010</year>
<volume>285</volume>
<issue>4</issue>
<fpage>2506</fpage>
<lpage>2514</lpage>
<name>
<surname>Parodi</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Sepúlveda</surname>
<given-names>F.J.</given-names>
</name>
<name>
<surname>Roa</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Opazo</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Inestrosa</surname>
<given-names>N.C.</given-names>
</name>
<name>
<surname>Aguayo</surname>
<given-names>L.G.</given-names>
</name>
<pub-id pub-id-type="pmid">19915004</pub-id>
</element-citation>
</ref>
<ref id="R76">
<label>76</label>
<element-citation publication-type="journal">
<source/>Proc. Natl. Acad. Sci. USA.
          <year>2010</year>
<volume>107</volume>
<issue>5</issue>
<fpage>1942</fpage>
<lpage>1947</lpage>
<name>
<surname>Friedrich</surname>
<given-names>R.P.</given-names>
</name>
<name>
<surname>Tepper</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Rönicke</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Soom</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Westermann</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Reymann</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>Kaether</surname>
<given-names>C.</given-names>
</name>
<name>
<surname>Fändrich</surname>
<given-names>M.</given-names>
</name>
<pub-id pub-id-type="pmid">20133839</pub-id>
</element-citation>
</ref>
<ref id="R77">
<label>77</label>
<element-citation publication-type="journal">
<source/>Neuroscience.
          <year>2011</year>
<volume>181</volume>
<fpage>175</fpage>
<lpage>188</lpage>
<name>
<surname>Ugrumov</surname>
<given-names>M.V.</given-names>
</name>
<name>
<surname>Khaindrava</surname>
<given-names>V.G.</given-names>
</name>
<name>
<surname>Kozina</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Kucheryanu</surname>
<given-names>V.G.</given-names>
</name>
<name>
<surname>Bocharov</surname>
<given-names>E.V.</given-names>
</name>
<name>
<surname>Kryzhanovsky</surname>
<given-names>G.N.</given-names>
</name>
<name>
<surname>Kudrin</surname>
<given-names>V.S.</given-names>
</name>
<name>
<surname>Narkevich</surname>
<given-names>V.B.</given-names>
</name>
<name>
<surname>Klodt</surname>
<given-names>P.M.</given-names>
</name>
<name>
<surname>Rayevsky</surname>
<given-names>K.S.</given-names>
</name>
<name>
<surname>Pronina</surname>
<given-names>T.S.</given-names>
</name>
<pub-id pub-id-type="pmid">21382448</pub-id>
</element-citation>
</ref>
<ref id="R78">
<label>78</label>
<element-citation publication-type="journal">
<source/>Mol. Med. 2011. V. 17. № 9–10.
          <year>2011</year>
<volume>17</volume>
<issue>9-10</issue>
<fpage>1107</fpage>
<lpage>1118</lpage>
<name>
<surname>Fabelo</surname>
<given-names>N.</given-names>
</name>
<name>
<surname>Martín</surname>
<given-names>V.</given-names>
</name>
<name>
<surname>Santpere</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Marín</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Torrent</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Ferrer</surname>
<given-names>I.</given-names>
</name>
<name>
<surname>Díaz</surname>
<given-names>M.</given-names>
</name>
</element-citation>
</ref>
<ref id="R79">
<label>79</label>
<element-citation publication-type="journal">
<source/>J. Neurochem.
          <year>2008</year>
<volume>105</volume>
<fpage>1656</fpage>
<lpage>1667</lpage>
<name>
<surname>Bar-On</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Crews</surname>
<given-names>L.</given-names>
</name>
<name>
<surname>Koob</surname>
<given-names>A. O.</given-names>
</name>
<name>
<surname>Mizuno</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Adame</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Spencer</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Masliah</surname>
<given-names>E.</given-names>
</name>
<pub-id pub-id-type="pmid">18248604</pub-id>
</element-citation>
</ref>
<ref id="R80">
<label>80</label>
<element-citation publication-type="journal">
<source/>Front. Aging Neurosci.
          <year>2014</year>
<volume>6</volume>
<fpage>1</fpage>
<lpage>12</lpage>
<name>
<surname>Jiang</surname>
<given-names>P.</given-names>
</name>
<name>
<surname>Gan</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Lin</surname>
<given-names>W.L.</given-names>
</name>
<name>
<surname>Yen</surname>
<given-names>S.H.</given-names>
</name>
<pub-id pub-id-type="pmid">24478697</pub-id>
</element-citation>
</ref>
<ref id="R81">
<label>81</label>
<element-citation publication-type="journal">
<source/>Mol. Aspects Med.
          <year>2009</year>
<volume>30</volume>
<issue>3</issue>
<fpage>111</fpage>
<lpage>122</lpage>
<name>
<surname>Brown</surname>
<given-names>A.J.</given-names>
</name>
<name>
<surname>Jessup</surname>
<given-names>W.</given-names>
</name>
<pub-id pub-id-type="pmid">19248801</pub-id>
</element-citation>
</ref>
<ref id="R82">
<label>82</label>
<element-citation publication-type="journal">
<source/>Elife.
          <year>2013</year>
<volume>2</volume>
<fpage>e00592</fpage>
<name>
<surname>Diao</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Burré</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Vivona</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Cipriano</surname>
<given-names>D.J.</given-names>
</name>
<name>
<surname>Sharma</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Kyoung</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Südhof</surname>
<given-names>T.C.</given-names>
</name>
<name>
<surname>Brunger</surname>
<given-names>A.T.</given-names>
</name>
<pub-id pub-id-type="pmid">23638301</pub-id>
</element-citation>
</ref>
<ref id="R83">
<label>83</label>
<element-citation publication-type="journal">
<source/>J. Neurosci.
          <year>2013</year>
<volume>33</volume>
<issue>6</issue>
<fpage>2605</fpage>
<lpage>2615</lpage>
<name>
<surname>Boassa</surname>
<given-names>D.</given-names>
</name>
<name>
<surname>Berlanga</surname>
<given-names>M.L.</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>M.A.</given-names>
</name>
<name>
<surname>Terada</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>J.</given-names>
</name>
<name>
<surname>Bushong</surname>
<given-names>E.A.</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Masliah</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>George</surname>
<given-names>J.M.</given-names>
</name>
<name>
<surname>Ellisman</surname>
<given-names>M.H.</given-names>
</name>
<pub-id pub-id-type="pmid">23392688</pub-id>
</element-citation>
</ref>
<ref id="R84">
<label>84</label>
<element-citation publication-type="journal">
<source/>Biomed. Res. Int.
          <year>2014</year>
<elocation-id>718732</elocation-id>
<name>
<surname>Alieva</surname>
<given-names>A.Kh.</given-names>
</name>
<name>
<surname>Shadrina</surname>
<given-names>M.I.</given-names>
</name>
<name>
<surname>Filatova</surname>
<given-names>E.V.</given-names>
</name>
<name>
<surname>Karabanov</surname>
<given-names>A.V.</given-names>
</name>
<name>
<surname>Illarioshkin</surname>
<given-names>S.N.</given-names>
</name>
<name>
<surname>Limborska</surname>
<given-names>S.A.</given-names>
</name>
<name>
<surname>Slominsky</surname>
<given-names>P.A.</given-names>
</name>
<pub-id pub-id-type="pmid">24804238</pub-id>
</element-citation>
</ref>
<ref id="R85">
<label>85</label>
<element-citation publication-type="journal">
<source/>Neuron.
          <year>2012</year>
<volume>75</volume>
<issue>6</issue>
<fpage>1008</fpage>
<lpage>1021</lpage>
<name>
<surname>Matta</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>van Kolen</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>da Cunha</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>van den Bogaart</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Mandemakers</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Miskiewicz</surname>
<given-names>K.</given-names>
</name>
<name>
<surname>De Bock</surname>
<given-names>P.J.</given-names>
</name>
<name>
<surname>Morais</surname>
<given-names>V.A.</given-names>
</name>
<name>
<surname>Vilain</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Haddad</surname>
<given-names>D.</given-names>
</name>
<pub-id pub-id-type="pmid">22998870</pub-id>
</element-citation>
</ref>
<ref id="R86">
<label>86</label>
<element-citation publication-type="journal">
<source/>Nat. Genet.
          <year>2013</year>
<volume>45</volume>
<issue>9</issue>
<fpage>965</fpage>
<lpage>967</lpage>
<name>
<surname>Nagy</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Ackerman</surname>
<given-names>S.L.</given-names>
</name>
<pub-id pub-id-type="pmid">23985682</pub-id>
</element-citation>
</ref>
<ref id="R87">
<label>87</label>
<element-citation publication-type="journal">
<source/>Nat. Genet.
          <year>2013</year>
<volume>45</volume>
<issue>9</issue>
<fpage>1013</fpage>
<lpage>1020</lpage>
<name>
<surname>Buchovecky</surname>
<given-names>C.M.</given-names>
</name>
<name>
<surname>Turley</surname>
<given-names>S.D.</given-names>
</name>
<name>
<surname>Brown</surname>
<given-names>H.M.</given-names>
</name>
<name>
<surname>Kyle</surname>
<given-names>S.M.</given-names>
</name>
<name>
<surname>McDonald</surname>
<given-names>J.G.</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>B.</given-names>
</name>
<name>
<surname>Pieper</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>W.</given-names>
</name>
<name>
<surname>Katz</surname>
<given-names>D.M.</given-names>
</name>
<name>
<surname>Russell</surname>
<given-names>D.W.</given-names>
</name>
<name>
<surname>Shendure</surname>
<given-names>J.</given-names>
</name>
<pub-id pub-id-type="pmid">23892605</pub-id>
</element-citation>
</ref>
<ref id="R88">
<label>88</label>
<element-citation publication-type="journal">
<source/>Neuron.
          <year>2013</year>
<volume>77</volume>
<issue>2</issue>
<fpage>243</fpage>
<lpage>250</lpage>
<name>
<surname>Osterweil</surname>
<given-names>E.K.</given-names>
</name>
<name>
<surname>Chuang</surname>
<given-names>S.C.</given-names>
</name>
<name>
<surname>Chubykin</surname>
<given-names>A.A.</given-names>
</name>
<name>
<surname>Sidorov</surname>
<given-names>M.</given-names>
</name>
<name>
<surname>Bianchi</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Wong</surname>
<given-names>R.K.</given-names>
</name>
<name>
<surname>Bear</surname>
<given-names>M.F.</given-names>
</name>
<pub-id pub-id-type="pmid">23352161</pub-id>
</element-citation>
</ref>
<ref id="R89">
<label>89</label>
<element-citation publication-type="journal">
<source/>Am. J. Med. Genet. A.
          <year>2015</year>
<volume>167A</volume>
<issue>2</issue>
<fpage>379</fpage>
<lpage>384</lpage>
<name>
<surname>Berry-Kravis</surname>
<given-names>E.</given-names>
</name>
<name>
<surname>Levin</surname>
<given-names>R.</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>H.</given-names>
</name>
<name>
<surname>Mathur</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Darnell</surname>
<given-names>J.C.</given-names>
</name>
<name>
<surname>Ouyang</surname>
<given-names>B.</given-names>
</name>
<pub-id pub-id-type="pmid">25424470</pub-id>
</element-citation>
</ref>
<ref id="R90">
<label>90</label>
<element-citation publication-type="journal">
<source/>Dev. Neurosci.
          <year>2012</year>
<volume>34</volume>
<issue>2-3</issue>
<fpage>88</fpage>
<lpage>100</lpage>
<name>
<surname>Qiu</surname>
<given-names>S.</given-names>
</name>
<name>
<surname>Aldinger</surname>
<given-names>K.A.</given-names>
</name>
<name>
<surname>Levitt</surname>
<given-names>P.</given-names>
</name>
<pub-id pub-id-type="pmid">22572629</pub-id>
</element-citation>
</ref>
<ref id="R91">
<label>91</label>
<element-citation publication-type="journal">
<source/>Exp. Anim.
          <year>2013</year>
<volume>62</volume>
<issue>2</issue>
<fpage>71</fpage>
<lpage>78</lpage>
<name>
<surname>Shinoda</surname>
<given-names>Y.</given-names>
</name>
<name>
<surname>Sadakata</surname>
<given-names>T.</given-names>
</name>
<name>
<surname>Furuichi</surname>
<given-names>T.</given-names>
</name>
<pub-id pub-id-type="pmid">23615300</pub-id>
</element-citation>
</ref>
<ref id="R92">
<label>92</label>
<element-citation publication-type="journal">
<source/>J. Neurosci.
          <year>2012</year>
<volume>32</volume>
<issue>29</issue>
<fpage>10021</fpage>
<lpage>10034</lpage>
<name>
<surname>Nguyen</surname>
<given-names>M.V.</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>F.</given-names>
</name>
<name>
<surname>Felice</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>X.</given-names>
</name>
<name>
<surname>Nigam</surname>
<given-names>A.</given-names>
</name>
<name>
<surname>Mandel</surname>
<given-names>G.</given-names>
</name>
<name>
<surname>Robinson</surname>
<given-names>J.K.</given-names>
</name>
<name>
<surname>Ballas</surname>
<given-names>N.</given-names>
</name>
<pub-id pub-id-type="pmid">22815516</pub-id>
</element-citation>
</ref>
<ref id="R93">
<label>93</label>
<element-citation publication-type="journal">
<source/>Front Cell Neurosci.
          <year>2014</year>
<volume>8</volume>
<fpage>245</fpage>
<name>
<surname>Cea-Del Rio</surname>
<given-names>C.A.</given-names>
</name>
<name>
<surname>Huntsman</surname>
<given-names>M.M.</given-names>
</name>
<pub-id pub-id-type="pmid">25202236</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>